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Abstract
In this thesis, a mathematical model for HIV and TB co-infection with TB
treatment among populations of Ethiopia is developed and analyzed. The
TB model includes an age of infection. We compute the basic reproduction
numbers RTB and RH for TB and HIV respectively, and the overall repro-
duction number R for the system. We find that if R < 1 and R > 1, then
the disease-free and the endemic equilibria are locally asymptotically stable,
respectively. Otherwise these equilibria are unstable. The TB-only endemic
equilibrium is locally asymptotically stable if RTB > 1, and RH < 1. How-
ever, the symmetric condition, RTB < 1 and RH > 1, does not necessarily
guarantee the stability of the HIV-only equilibrium, but it is possible that
TB can coexist with HIV when RH > 1. As a result, we assess the impact of
TB treatment on the prevalence of TB and HIV co-infection.
To derive and formulate the nonlinear differential equations models for HIV
and TB co-infection that accounts for treatment, we formulate and analyze
the HIV only sub models, the TB-only sub models and the full models of HIV
and TB combined. The TB-only sub model includes both ODEs and PDEs
in order to describe the variable infectiousness and effect of TB treatment
during the infectious period.
To analyse and solve the three models, we construct robust methods, namely
the numerical nonstandard finite difference methods (NSFDMs). Moreover,
we improve the order of convergence of these methods in their applications
to solve the model of HIV and TB co-infection with TB treatment at the
population level in Ethiopia. The methods developed in this thesis work
and show convergence, especially for individuals with small tolerance either
to the disease free or the endemic equilibria for first order mixed ODE and
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PDE as we observed in our models.
Keywords and expressions: HIV, TB, Nonstandard finite difference meth-
ods, Basic reproduction number, Stability, Co-infection.
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vNotations and definitions of some terms
• AIDS: Acquired Immunodeficiency Syndrome;
• ARV: Antiretroviral Virus;
• CPT: Cotrimoxazole prophylactic treatment;
• DOTS: Directly Observed Treatment, Short-Course;
• DR-TB: drug resistant TB;
• DS-TB: drug-sensitive TB;
• EDHS: Ethiopian Demographic Health Survey;
• IPT: Isoniazid Preventive Therapy;
• MOH: Federal Ministry of Health;
• MTB: Mycobacterium tuberculosis;
• NSFDMs: Nonstandard finite difference methods;
• ODEs: ordinary differential equations;
• PDEs: partial differential equations;
• PLWHA: People Living with HIV/AIDS;
• TB: Tuberculosis;
• UNAIDS: United Nations Joint Program on HIV and AIDS;
• WHO: World Health Organization;
• SI: susceptible, infectious;
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• SIS: susceptible, infectious, susceptible epidemiological compartments;
• SEE: stable epidemic equilibrium;
• SDFE: stable disease free equilibrium;
• UEE: unstable epidemic equilibrium;
• UDFE: unstable disease free equilibrium;
• Age of infection is the time lapsed since infection;
• Antiretroviral therapy (ART) is the recommended treatment for HIV
infection. ART involves taking a combination (regimen) of three or
more anti-HIV medications daily. ART prevents HIV from multiply-
ing and destroying infection-fighting CD4 cells. This helps the body
fight off life-threatening infections and cancer. ART can not cure HIV,
but anti-HIV medications help people infected with HIV live longer,
healthier lives;
• Co-infection is the infection of a host by at least two different types of
pathogens. TB and HIV dynamics have a correlation, as HIV weakens
the immune system of the host, which creates a proper medium for
MTB to infect the host. Therefore, in areas with high HIV prevalence,
TB is one of the main causes of death;
• Drug resistant TB (DR-TB) is a disease (usually pulmonary) caused by
Mycobacterium Tuberculosis strains resistant to one or more anti-TB
drugs. TB organisms resistant to the antibiotics used in its treatment
are widespread and occur in all countries surveyed. Drug resistance
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emerges as a result of inadequate treatment and once TB organisms
acquire resistance. They can spread from person to person in the same
way as drug-sensitive TB;
• Human Immunodeficiency Virus (HIV) is the virus that causes HIV
infection. During HIV infection, the virus attacks and destroys the
infection-fighting CD4 cells of the bodys immune system. Loss of CD4
cells makes it difficult for the immune system to fight infections;
• HIV-1 is a type of HIV which has been classified into three groups:
M (major), O (outlier) and N (non-M and non-O). The global AIDS
epidemic is currently dominated by the group M HIV-1 virus. Group
M can further be divided into subtypes or clades, of which nine have
been designated A to K (M clades) and O. M and O show 55-70;
• Macrophages- are white blood cells within tissues, produced by the di-
vision of monocytes;
• Multi-drug-resistant TB (MDR-TB) is caused by organisms that are re-
sistant to the most effective anti-TB drugs (isoniazid and rifampicin).
MDR-TB results from either infection with organisms which are already
drug-resistant or may develop in the course of a patient’s treatment.
This form of TB does not respond to the standard six month treatment
with first-line anti-TB drugs and can take two years or more to treat
with drugs that are less potent, more toxic and much more expensive;
• Resistant strains are those that differ from sensitive strains in their
capacity to grow in the presence of higher concentrations of a drug;
• Sensitive strains (sensitive strains of Mycobacterium TB) are those
that have never been exposed to the main anti-tuberculosis drugs (wild
strains) and respond to these drugs, generally in a remarkably uniform
manner;
• TB incidence and prevalence are central to the rate of tuberculosis
transmission. TB incidence is defined as the rate of appearance of new
TB cases per unit time. TB prevalence is the proportion of infected
individuals at one point in time, or over a short time period. The
measurement of incidence and prevalence is often based on stratifica-
tion of the population by a variety of factors, such as age, ethnicity, etc;
• Treatment: control of tuberculosis is managed by two types of treat-
ment. The treatment of latent TB is called chemoprophylaxis and
treatment of active TB is called therapeutics. Treatment of TB lasts
long; therefore control strategies have been developed for compliance
to TB treatment. DOTS (Directly Observed Treatment, Short-Course)
are a treatment program used for compliance with treatment of drug-
sensitive TB. Another control program is DOTS-plus, which is devel-
oped for compliance with treatment of drug-resistant TB. A good public
health treatment strategy combines different control strategies to con-
trol all types of TB infections.
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Chapter 1
General introduction
The spread of human immunodeficiency virus/acquired immune deficiency
syndrome (HIV/AIDS), tuberculosis (TB) and malaria across the world poses
major global health challenges of this time [29, 56, 60].
In [52], according to the recent estimates by the United Nations Program
on HIV/AIDS (UNAIDS) global report, 35.3 (32.2–38.8) million people were
living with HIV/AIDS, worldwide in 2012; more than a half of them in
Sub-Saharan Africa and nearly about a fifth in South and South-East Asia.
According to MOH office report [23, 28], the overall prevalence of HIV infec-
tion was 2.4 percent and 1, 216, 908 people were living with HIV/AIDS in
Ethiopia.
Globally, in 2013, an estimated nine million people developed TB and 1.5
million died from the disease [59]. In Ethiopia, TB has been recognized as a
major public health problem for more than half a century, and claiming the
lives of thousands of Ethiopians every year. In 2011 WHO global TB report,
Ethiopia ranks 7th among the 22 high TB burden countries in the world and
one of the top three in Africa, with regard to the prevalence of TB [58, 60].
MDR-TB is an emerging challenge for TB control globally. Ethiopia is among
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these countries, at the end of February 2012, a total of 437 cases of MDR-TB
patients were enrolled on treatment in three MDR-TB centers in Ethiopia.
Regarding their outcome of treatment, success was documented in 72 pa-
tients while 43 died and 6 defaulted from treatment [26, 29, 30, 58, 59, 60].
An estimated 1.1 million (13 percent) of the nine million people who devel-
oped TB were HIV-positive. The African region accounts for about four out
of every five HIV-positive TB cases and TB deaths among people who were
HIV positive [56, 59]. Among people with active TB, more than 22 percent
of them are HIV positive. Co-infection of HIV with TB greatly increases the
probability for an individual to progress from latent to active TB and TB is
also the most common cause of AIDS-related deaths [45, 61].
In this thesis; firstly, we focus on considering the age of infection in TB when
modeling the dynamics of TB with treatment from a mathematical point
of view. Lastly, we include the age of infection on the dynamics of HIV
and TB co-infections with TB treatment. Hence, the mathematical models
considered or developed are described by autonomous systems of non-linear
partial and ordinary differential equations. Therefore, we design a special
class of numerical methods, known as Nonstandard Finite Difference Meth-
ods (NSFDMs) as is mentioned in [32] and others fail to investigate the
applicability of such methods for non-linear PDE models and to improve the
order of convergence of these methods (both for ODE and PDE models) in
biology and ecology.
As far as possible, most of the terminologies considered in this thesis are
adopted from MOH, WHO and UNAIDS in Ethiopia. We have been work-
ing in collaboration with the staffs of MOH to access the data made.
A concise background for HIV-TB co-infection with TB treatment is pre-
sented in the next section.
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1.1 HIV-TB co-infection with TB treatment
in Ethiopia
The global adoption of WHO has enabled more than 55 million people in-
fected with TB to receive treatment. It also prevented up to 7 million deaths
between 1995 and 2010. In 2013, an estimated 9.0 million people developed
TB and 1.5 million died from the disease in this year alone and 2.5 million
new HIV infections annually [4, 39, 56, 58].
In Ethiopia, the number of notified TB cases has been steadily increasing
since 1996 from 79,095 to reach a peak of 159,017 cases in 2011. However,
the number of notified TB cases has shown a marked decline over the last
three successive years as shown in the table 1.1 below. It is shown a decline
of 8 percent and 13 percent over the next two successive years (2012 and
2013) and the last one year, respectively [26, 29].
Number of notified TB cases in Ethiopia: 1996 - 2014
yearNumber of notified TByear Number of notified TB
1996 79,095 2005 125,135
1997 59,611 2006 123,009
1998 70,714 2007 129,743
2000 92,759 2008 141,909
2001 95,826 2009 149,146
2002 110,998 2010 154,406
2003 118,276 2011 159,017
2004 124,223 2012 146,367
2013 130,614 2014 115,821
Table 1.1: Trend in the number of notified TB cases over 19 years, Ethiopia.
In 2011, a total of 159,017 cases of TB were registered for treatment. The
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TB cure rate for new smear positive pulmonary TB registered is 66.5 percent
in 2011. A death rate of 2.6 percent among TB patients registered for treat-
ment in a year would imply the need to strength quality of TB patient care
along with fostering early diagnosis and treatment. Similarly the death rate
(proportion of TB cases who died while on anti-TB treatment among TB
cases registered for treatment during same time period) among the notified
new smear positive pulmonary TB (PTB+) cases in 2012 is 2.8 percent at
national level. In 2013, a total of 130,614 TB cases were reported with a
TB case notification rate of 152 per 100,000 populations. Out of 130,614
cases reported in the year; 33.4 percent were smear positive pulmonary TB,
34.5 percent were smear negative pulmonary TB and 32.1 percent were extra
pulmonary TB [26, 29]. The HIV pandemic presents a massive challenge to
the control of tuberculosis at global and national level. It is evidenced that
the synergy between TB and HIV/AIDS is strong, especially in high HIV
prevalence settings. TB is the leading cause of morbidity and mortality, and
HIV is driving the TB epidemic in many countries, especially in Sub-Saharan
Africa including Ethiopia [29].
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Figure 1.1: Trend in the number of people living with HIV/AIDS who ac-
cessed chronic HIV care (2006-2013) [26,29].
From the above figure, a linear increase has been observed in the number of
people living with HIV/ADIS (PLWHA) ever enrolled, ever started and cur-
rently on ART over the past seven years; in particular, there was an increase
between Ethiopian fiscal year (EFY) 2004 and EFY 2005 from 666,147 to
744,339 for PLWHA ever enrolled in HIV/AIDS care (+78,192), from 379,190
to 439,301 for those ever started (+60,111), and from 274,708 to 308,860 for
those currently on ART (+34,152).
To understand the epidemiology of TB and HIV co-infection in Ethiopia,we
cross-matched incident TB cases reported to routine surveillance data during
2007-2010 with cases in the HIV/AIDS registry [4]. Of 176,739 TB case-
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patients 35,140 (20 percent) had known HIV infection. TB rates for persons
with HIV declined from 31 to 15 percent for the first four years and slightly
increased fom 17 to 20 percent for the last two years during 2007-2012. In
2010, 69 and 39 percent of patients co-infected with TB-HIV were put on
CPT and ART respectively in the same registry [10, 11, 12]. In Ethiopia,
the overall prevalence of HIV infection is 2.4 percent and Minister of Health
office reported 1,216, 908 people were living with HIV/AIDS.
In 2010, of 66,955 TB cases 9,809 (15 percent) patients had known HIV in-
fection [21, 26]. Of 68,169 TB cases 9,285 (14 percent) patients had known
HIV infection in 2013/2014. When a person is infected with HIV, they are at
an increased risk of also contracting TB. Co-infection with TB can also mean
an accelerated progression to AIDS. Most leading international bodies, such
as the WHO and UNAIDS, agree on the importance of a collaborative ap-
proach to dealing with TB-HIV co-infection, including testing and treatment
[33]. TB/HIV collaborative activities are essential to reduce the burden of
TB among people living with HIV/AIDS and to reduce the burden of HIV
among TB patients. These activities include establishing mechanisms for
collaboration between TB and HIV programs; infection control in health-
care and congregate settings; HIV testing and counseling of TB patients and
to refer TB patients infected with HIV to HIV services such as CPT and
ART [8, 26, 41].
In 2011, among people with active TB, more than 22 percent of them are
HIV positive. Co-infection of HIV with TB increases greatly the probability
of progressing from latent to active TB [23].
The following table shows the number/proportion of TB patients tested for
HIV, HIV-TB co-infection and their co-infection rate 2007-2014.
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Number of people tested for TB and co-infected with HIV
YearTB patients tested for HIVHIV-TB co-infectedco-infection rate
2007 20,723 6,342 31
2008 33,021 7,891 24
2009 56,040 11,098 20
2010 66,955 9,809 15
2011 68,169 9,285 14
2012 75,137 11,271 15
2013 82,802 11,592 14
2014 90,034 11,705 13
Table 1.2: Sources [8, 26, 41].
Some of the important associations between the epidemiology of HIV and
TB co-infections are:
• TB is harder to diagnose and treat in HIV positive people,
• TB facilitates the progression of HIV to AIDS,
• TB progresses faster in HIV positive infected people,
• HIV accelerates TB from latent to active and had impact on the preva-
lence of TB diseases,
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• HIV facilitates the progression of TB to MDR-TB.
1.2 Literature review
Many literatures relevant to this research were reviewed, developed and an-
alyzed through mathematical models by different researchers. The NSFD
methods were explored by many researchers to solve problems in the biolog-
ical sciences and other areas. This section gives an overview on some chosen
models on HIV, TB (including drug resistant TB) and their co-infections.
Maliyoni [41] formulated and analyzed a two-strain TB model with diagnosis,
treatment, and health education. Their theoretical study was assessed the
impact of the control strategies on the transmission dynamics of MDR-TB
(with Malawi as a case study). They noted that the results presented were
general and could be applied to other settings because neither the model,
nor the parameters values represent characteristics unique of Malawi. The
effective reproduction number was computed and used to compare the effect
of each intervention strategy on the MDR-TB dynamics.
In [31, 76] as most traditional compartmental models in mathematical epi-
demiology descend from the classical Susceptible Infecected Recovered(SIR)
model and epidemic model with fractional derivative and non-linear incidence
advance in difference equations of Kermack-McKendrick, where the popula-
tion is divided into the classes of susceptible, infected, and recovered individ-
uals. All of the models cited assumed the homogeneity of the infected class
and individuals in that compartment share the same epidemiological param-
eters. In reality, however, as time elapses and the disease develops within the
host, its infectivity might continuously change. The purpose of their paper
was to incorporate this feature into the Susceptible Exposed Infecected Re-
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covered (SEIR) model. Models keeping track of an individuals infection age
had existed for particular diseases, for instance TB and HIV/AIDS. However,
their general SEIR was formulated as a system of delay differential equations
with infinite delay. The novelty of their model was that they allowed varying
infectivity of the infected individuals as a function of the age of infection.
This assumption leads to a system of differential equations with distributed
infinite delay. They have shown that several standard theorems in mathe-
matical epidemiology can be extended to this kind of SEIR model, and the
basic reproduction number has been calculated. In the future, it would be
interesting to prove the global stability of the endemic equilibrium.
Phillips [36] explained, TB infection can be latent or active. In the latent
form it was held at bay by the immune system, did not cause illness, and
could not be spread from one person to another. In the active state it can be
transmitted to others, and severe illness and death could result if it was not
diagnosed and effectively treated. Anyone who is latently infected is at risk
of developing active TB later in life if his or her immune system fails. Unlike
HIV infection, which is not spread by casual contact, TB infection can be
acquired by healthy individuals who inhale mycobacterium tuberculosis. TB
is more likely to be spread in crowded living conditions (such as homeless
shelters, prisons, or crowded homes) and areas of high prevalence in which
uninfected individuals were in close proximity with persons with active TB.
Several studies [9, 10] have presented a two-strain model, in which the drug-
resistant strain was not treated, and latent, infectious and treated individuals
might be re-infected with the drug-resistant strain. Each strain has a different
basic reproduction number, and there were three equilibrium points (no dis-
ease, coexistence of both strains, and only the drug-resistant strain). Without
acquisition of drug resistance, there was an additional equilibrium with only
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the drug-sensitive strain. The authors discussed stability of the equilibria
and found, interestingly, areas of parameter space of positive measure where
coexistence of the strains was possible; they reported that coexistence was
rare when drug resistance was mainly primary (resulting from transmission)
but almost certain if the resistant strain was the result of acquisition, for
example under poor treatment. Neglecting disease-induced death and set-
ting the transmission parameter equal for the two strains, they were able
to prove that the disease-free equilibrium is globally asymptotically stable if
both basic reproduction numbers are less than unity.
Although TB is currently well-controlled in most countries, recent data in-
dicated that the overall global incidence of TB was rising as a result of
resurgence of disease in Africa and parts of Eastern Europe and Asia (Dye,
2006). In these regions, the emergence of drug-resistant TB and the conver-
gence of the HIV and TB epidemics have created substantial new challenges
for disease control.
TB treatment was long and hard to complete. Therefore, there was a need
for a program to force tuberculosis patients to complete their treatment. For
this purpose, DOTS (Directly Observed Treatment, Short-Course) was used
as an effective strategy for controlling TB epidemics [7].
Blower et al [6]. developed a model for designing effective control strategies
to determine levels of eradication of TB. Treatment failure can lead to drug
resistance, which is a challenge to control programs, as these drug-resistant
strains are more difficult to treat. One-strain models account only for drug-
sensitive cases only. To account for drug resistance, Blower et al [6]. built a
two-strain model, a linked control model, by integrating drug resistance.
Mathematical models for the dynamics of multi-drug resistant tuberculosis
in Mali; assessing the impact of control strategies was developed by Maliyoni
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[40]. In their thesis, they have presented and analyzed a basic tuberculosis
model which was modified into a two-strain TB model with diagnosis, treat-
ment and health education in Malawi. The main objective of their study was
to assess the impact of the control strategies mentioned above on the trans-
mission dynamics of MDR-TB only in Malawi. Qualitative analysis of the
models shows that the model has two equilibria; the disease free equilibrium
and endemic equilibrium. It was found out that whenever reproductive num-
ber is less than unity, the disease free equilibrium is locally asymptotically
stable and becomes unstable whenever the reproductive number becomes
greater than unity.
There were a lot of mathematical models describing tuberculosis, but only
few of them concerning drug resistance. They were often deterministic al-
though some stochastic models, such as Markov chain models, were also
used in general cases. Two leading experts in this field, Castillo-Chavez and
Song [9], contributed to a better understanding of the tuberculosis dynamics
and drug resistance. In transmission model, several authors [6, 8, 9, 11, 57]
have developed ordinary differential equation models with drug-sensitive and
drug-resistant strains.
E.F. du Toit [19] proposed a linear differential equations model for showing
the co-infection dynamics of HIV-1 and Mycobacterium tuberculosis. In the
research, a model is proposed to indicate the populations of both pathogen
as well as key information factors, such as the overall infected cell popula-
tion and antigen-presenting cells. Their treatment simulation showed both
the effect that changes in HIV has on TB, and the effect that changes in
TB has on HIV. Finally, they listed new research possibilities stem from this
co-infection model that can be extended as to be the latest knowledge on
TB and HIV. For TB, this would mean the effect of drug resistant TB would
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have to be considered and the model must be adjusted for the specific types
of TB accordingly.
Santosh Ramkissoon et.al. [50] developed a modeling HIV and MTB co-
infection including combined treatment strategies. They had presented a new
model which was able to simulate HIV and TB co-infection and test various
combined treatment strategies. They also tested combined treatment with
different timings for each therapy. In their conclusion, they recommended
that further work could address mechanisms of HIV disease progression, sup-
pressed, latent and active MTB infection, and tubercle formation and TB of
drug resistant could be modeled. As a step toward multi-scale simulation the
host pathogen model could be embedded in a population-level of epidemio-
logical model.
Kirschner [16] designed Dynamics of Mycobacterium tuberculosis and HIV-1
co-infection. Here a simple mathematical model was developed to describe
the interaction of the immune system’s key players, T cells and macrophages,
with the pathogens HIV and Mycobacterium tuberculosis. It showed that
the presence of Mycobacterium tuberculosis in the HIV-infected individual
worsens the clinical picture and therefore, treatment of TB in HIV-infected
individuals could have been a profound effect on their progression to AIDS.
When designing treatment, a drug that suppresses bacterial growth, as op-
posed to enhancing the bacterial death rate, would likely be more effective.
They recommended screening HIV-infected individuals at high risk for TB
(or showing any clinical signs of TB), and then initiation of a complete course
of treatment for TB positive individuals. They concluded that further inves-
tigation will be needed to examine the role of development of drug-resistance
in both TB (MDR-TB) and TB-HIV infections.
Roeger [38] proposed mathematical modeling of TB and HIV co-infections.
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Their model consisted of a system of eight differential equations that was
introduced to model the joint dynamics of TB and HIV by dividing the to-
tal population in to different epidemiological subgroups, which allowed the
incorporation of both infections. The simulation results showed that the pro-
gression of latent to active TB is faster in people with HIV than in people
without. The presence of HIV could lead to the co-existence of TB and HIV.
The numerical results suggested that to reduce (control) the impact of TB,
investing more in reducing the prevalence of HIV could be an effective option.
In the conclusions, they recommended that detailed models that take into
accounts various forms of TB treatment (latent and active TB), the danger
of increasing the prevalence of antibiotic resistant TB and their relation to
HIV treatment must be incorporated into models of HIV/TB co-infection if
further progress is to be made.
The mathematical analysis of the transmission dynamics of HIV and TB
co-infection in the presence of treatment was developed by Sharomi et al
[44]. By combining some assumptions and definitions, the realistic determin-
istic model for the transmission dynamics of HIV and TB in a population
is designed and rigorously analyzed using fifteen linear ordinary differential
equations with treatment strategies using burification methods. Their study
showed that the prospect of effectively controlling the spread of HIV and TB
in a community, using effective treatment for both diseases, is bright.
Villanueva et al. [56] developed NSFD schemes to solve the numerical so-
lution of a mathematical model of infant obesity with constant population
size. Their model consists of a system of coupled nonlinear ordinary differen-
tial equations. The numerical results showed that their methods have better
convergence properties as compared to the classical Euler or the fourth-order
Runge-Kutta methods and the Matlab routines in the sense that these rou-
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tines give negative values for some of the state variables.
Construction and analysis of efficient numerical methods to solve mathemat-
ical models of TB and HIV co-infection was conducted by Obaid Ahmed [32].
In his study competitive unconditionally stable NSFDMs were proposed for
solving a TB-only sub-model and a full HIV-TB co-infection model repre-
sented by a nonlinear system of ordinary differential equations. Numerical
results presented, confirmed the applicability of the proposed NSFDMs for
the biological systems. These methods preserved the positivity of solutions
and converging to stability properties of the equilibria for arbitrary step-sizes
while the solutions obtained by other numerical methods experience difficul-
ties in either preserving the positivity of the solutions or in converging to the
correct equilibria. Finally they suggested that investigating the applicability
of their methods for partial differential equation models in biology, and im-
proving the order of convergence of these NSFDMs (both for ODE and PDE
models) still needs further study.
According to the best of our knowledge, we could hardly find research on
mathematical modeling of HIV and TB co-infections that incorporate TB
treatment in nonlinear ordinary and partial differential equations models.
But from biological and medical perspectives, the reader who wishs to look
at the work of HIV and TB co-infections may refer to the works in [14, 19,
31, 32, 34, 36, 38, 39, 43, 44, 45, 51, 50, 56, 92, 96, 97, 98, 99, 100, 101, 102,
104] and the reference there in.
Some other works dealing with the dynamics of TB only can be found in [4,
5, 6, 7, 8, 9, 10, 11, 15, 17, 18, 34, 35, 39, 40, 41, 42, 43, 52, 53, 54, 57, 65,
90, 91, 93, 94, 95, 103] whereas works dealing with the dynamics of HIV only
are available in [1, 34, 39, 40, 43, 61].
From this background our study investigates the applicability of NSFD meth-
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ods for partial differential equation models in epidemiology and improves its
order of convergence by improving the mathematical model of [32].
1.3 Outline of the thesis
This thesis deals with the construction and analysis of nonstandard finite
difference numerical methods for solving HIV-TB co-infection with TB treat-
ment models. The case of Ethiopian population is considered. At the be-
ginning, we studied the sub-models (HIV-only and TB-only) and then the
full model (HIV-TB co-infection). More specific details are provided in the
following lines.
Chapter 1 deals with the general introduction on the main goal of this thesis
where a global literature review on HIV /TB co-infection with TB treatment
and the NSFD methods have been thoroughly detailed. In chapter 2, we de-
velop and analyze a mathematical model describing the dynamics of TB with
age of infection. The model accounts for one-strain distributed-delay model
at the age of infection with drug sensitive TB. The analysis presented in this
chapter introduces a function p(α) (0 ≤ p(α) ≤ 1 ) as the small proportion
of the sensitive strain that is active at the infection age α to distinguish ac-
tive TB and inactive TB. The drug resistant strain accounts for active TB
only. Drug-resistant and drug-sensitive strains are modeled, but only the age
of the infection with drug-sensitive strain is considered. Here, the density
function is(α, t) is a function of two independent continuous variables that
has a PDE in the model which makes the model more complicated than the
models based on ODE. In this chapter, we also try to analyse the effect of
p(α) and the per-capita contact rate on the dynamics of the TB model in
both strains.
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Chapter 3 investigates the above approach by studying a co-infection of the
HIV-TB model. In this chapter, the TB model developed in chapter 2 is com-
bined with the HIV model to formulate the model of the HIV-TB co-infection.
Therefore, we study the stability of the steady states. In particular, we study
the stability of the disease-free equilibria, and the endemic equilibria. To this
end, the effects of TB treatment on the dynamics of HIV-TB co-infections
are investigated.
In chapter 4, we propose effective numerical methods (NSFDMs) that solve
the TB models with both TB strains as proposed in chapter 2. We also con-
struct and analyze the NSFDMs that solve the HIV-TB co-infection model
presented in chapter 3. We show the stability and applicability of the meth-
ods for biological systems and for the systems presented here.
Finally some conclusions are drawn from this study. These are also men-
tioned in chapter 5 where scope of some future research are indicated.
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Chapter 2
Analysis of the TB model with
the age of infection
In this chapter, we develop and analyze a mathematical model describing the
dynamics of TB with the age of infection. In this model, the dynamics of
both drug-sensitive and resistant strains of TB are considered. The model
accounts for a one-strain distributed-delay model at the age of infection with
drug sensitive TB.
2.1 Introduction
Mathematical models have played a key role in the formulation of TB control
strategies and the establishment of interim goals for intervention programs.
Most of these models are of the SEIR or SIS type in which ndividuals in the
host population are categorized by their infection status such as susceptible,
exposed (infected but not yet infectious), infectious and recovered (here a re-
covered individual can become susceptible again). One of the main attributes
of these models is that the force of infection (the rate at which a susceptible
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individual leaves the susceptible class and moves into an infected category,
i.e. become infected) is a function of the number of infectious hosts in the
population at any time t and is thus a nonlinear term. Other transitions,
such as the recovery of infectious individuals and the death of others, are
modeled as linear terms with constant coefficients [9, 10].
Globally, 3.5 percent of new TB infections and 20.5 percent of previously
treated TB cases were estimated to have had MDR-TB in 2013. However,
much higher levels of resistance and poor treatment outcomes are of major
concern in some parts of the world. There is a case of MDR-TB that is
resistant to the first two lines of drugs, namely: isoniazid and rifampicin.
For most patients diagnosed with MDR-TB, the WHO recommends treat-
ment for 20 months with a regimen that includes second line anti-TB drugs.
Hence, among the estimated 480 000 people having developed MDR-TB that
year, a total of 97 000 patients were put on MDR-TB treatment [59].
In [52], M.R. Silvia’s analysis provides new insights for the interpretation of
epidemiological estimates of fitness of MDR-TB strains. Their results im-
plied that the potential for the spreading of the drug-resistant strain cannot
be evaluated simply by measuring its relative fitness value, but should be
evaluated within the context of several others factors, including the treat-
ment, healing rates, treatment efficacy and relative fitness.
Zhilan Feng, Wenzhang Huang, and Carlos Castillo-Chavez proved the global
stability of the endemic equilibrium of an ODE model of TB that were de-
veloped previously (see Castillo-Chavez and Feng, 1997a) [8, 65] . They also
constructed a TB model with a distributed delay to study the effect of vari-
able periods of latency on the transmission dynamics of TB at the population
level. The purpose of their paper was to look at the effects of variable (rather
than exponentially distributed) periods of latency on the dynamics of TB.
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M. Maliyoni [41] formulated and analyzed a two-strain TB model in Malawi
with diagnosis, treatment, and health education as their main objective was
the theoretical study (as a case study). They noted that the results pre-
sented were general and could be applied to other settings because neither
the model nor the parameter values did not represent characteristics unique
to Malawi. The effective reproduction number was computed and used to
compare the effect of each intervention strategy on the MDR-TB dynamics.
Traditional compartmental models in mathematical epidemiology descend
from the classical SIR model of Kermack and McKendrick, where the popu-
lation is divided into the classes of susceptible, infected, and recovered indi-
viduals as already mentioned here above. Most of the model used assumed
the homogeneity of the infected class and individuals in that compartment
share the same epidemiological parameters [31]. In reality, however, as time
elapses and the disease develops within the host, its infectivity might contin-
uously change. The purpose of their paper was to incorporate this feature
into the SEIR model. Models that keep track of an individual’s infection age
had existed for some particular diseases, for instance TB and HIV/AIDS.
However, their general SEIR model was formulated as a system of delay
differential equations with infinite delay. The novelty of the model was to
consider varying infectivity of the infected individuals as a function of the age
of infection. They had shown that several standard theorems in mathemati-
cal epidemiology can be extended to this kind of SEIR model, and the basic
reproduction number was calculated. In the future, it would be interesting
to prove the global stability of the endemic equilibrium.
Moualeu in their thesis [15] presented a nonlinear extended deterministic
model for the transmission dynamics of TB, based on realistic assumptions
and data collected from the WHO. This model enables a comprehensive qual-
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itative analysis of various aspects in the outbreak and control of TB in Sub-
Saharan Africa countries and successfully reproduces the epidemiology of TB
in Cameroon for the period of 1994 to 2010. Some particular properties of
the model and its solution have been presented using the comparison theo-
rem applied to the theory of differential equations. The existence and the
stability of a disease free equilibrium has been discussed using the Perron-
Frobenius theorem and Metzler matrices.
The drug-resistant phenotype may be acquired among those treated for drug-
sensitive active disease, or directly transmitted to susceptible individuals. TB
is affecting everyone no matter the sex or age group. Poverty is a risk factor
for developing TB, which places Ethiopia as a high-risk environment. The
country is one of the least developed in the world. Among the total smear
positive TB cases reported in 2009-2010, 55.5 percent were males, 7.5 per-
cent were children of age less than 14 years old, and 2 percent were above
the age of 65. The group age between 15 to 34 was found to be the most
affected with TB, accounting for 62 percent of notified new smear positive
TB cases [54]. The disproportionately large burden of TB in this age group,
which comprises a large part of the total workforce in the country, could be
contributing to poverty. Some people of the same age group are parent of
young children and this can also be heavily contributing to the transmis-
sion of TB in the household and to the overall burden of childhood TB in
the country [28, 54]. C. Colijn reviewed the literature on the mathematical
modeling of tuberculosis dynamics [10]. Multiple models exist, encapsulating
different assumptions about the dynamics of progression from latent infec-
tion to active disease, the nature of re-infection and the subsequent partial
immunity, and the complexities of different TB strains as well as HIV. They
described results from two new models of TB: a spatial stochastic model and
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a delay differential equation model. The stochastic model indicates that if
the disease transmission is indeed local, this may reduce the effectiveness of
widely applied preventative treatment. Both models allow us to examine the
portion of new disease that is due to exogenous re-infection without having
to specify the portion of new infections destined to be fast progressors. The
specific implementation of partial immunity does not affect the estimated
contribution of re-infection to disease levels, but spatial effects do.
Although TB is currently well-controlled in most countries, recent data indi-
cated that the overall global incidence of TB is rising as a result of resurgence
of disease in Africa and parts of Eastern Europe and Asia (Dye, 2006). In
these regions, the emergence of drug-resistant TB and the convergence of the
HIV (human immunodeficiency virus) and TB epidemics have created sub-
stantial new challenges for disease control. TB treatment is long and hard
to complete. Therefore, there is a need for a program to force TB patients
to complete their treatment. For this purpose, DOTS (Directly Observed
Treatment, Short-Course) is used as an effective strategy for controlling TB
epidemics [7]. One-strain models account only for drug-sensitive cases only.
Blower et al. developed a model for designing effective control strategies to
determine levels of eradication of TB. Treatment failure can lead to drug
resistance, which is a challenge to control programs, as these drug-resistant
strains are more difficult to treat. To account for drug resistance, Blower
et al. built a two-strain model, a linked control model, by integrating drug
resistance [7, 53].
There were a lot of mathematical models describing tuberculosis, but only
few of them concerning drug resistant. They were often deterministic al-
though some stochastic models, such as Markov chain models, were also
used in general cases. Two leading experts in this field, Castillo-Chavez and
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Song, contributed a review. In transmission model several authors developed
ordinary differential equation models with drug-sensitive and drug resistant
strains, such as Blower et al, Castillo-Chavez and Feng in [6, 9, 11, 57].
In [9], drug sensitive and resistant strains were modeled, but only the age
of the infection with drug sensitive strain was considered. They introduce a
function p(α) as the proportion of the sensitive strain that is active at the
infection age α to distinguish TB and inactive TB. For the drug resistant
strain, they only account active TB. MDR-TB is an emerging challenge for
TB control programs globally; Ethiopia ranks the 7th among the 22 high
burden countries in the world and one of the top three in Africa, with regard
to the prevalence of TB [26, 58]. At the end of February 2012, from a total of
870 cases of MDR-TB only 437 patients were enrolled on treatment in three
MDR-TB centers in Ethiopia. Regarding their outcome of treatment, success
was documented in 72 patients while 43 died and 6 defaulted from treatment.
The estimated annual number of MDR-TB patients was 1500-2500 cases in
2013-2014. The prevalence of MDR-TB is increasing at an alarming rate
from a baseline rate of 1.6 percent among new TB cases in 2005 to current
level of 2.3 percent in 2014 [30].
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The following table shows the prevalence, incidence and mortality rate of
TB in Ethiopia for 19 years from 1990 to 2014.
Number of notified TB cases per 100,000 in Ethiopia: 1996 - 2014
YearIncidence of TBPrevalence of TB Mortality rate of TB
1990 425 367 49
1995 480 419 48
2000 430 421 41
2005 330 342 29
2006 314 324 27
2007 296 308 25
2008 280 293 23
2009 265 280 21
2010 251 261 20
2011 237 258 18
2012 172 181 24
2013 154 170 29
2014 200 210 30
Table 2.1: Number of notified TB cases per 100,000 in Ethiopia: 1996 - 2014
[26, 29, 58].
The following figure shows that the prevalence, incidence and mortality rate
of TB (sensitive strain) cases in Ethiopia.
23
Figure 2.1: Trend of TB prevalence, incidence and mortality rates in
Ethiopia: 1990-2014 [26, 29].
This figure shows the prevalence, incidence, and mortality rate of TB per
100,000 of population.
The estimates of TB prevalence rate in Ethiopia had increased during the
first five years and declined for the second 18 years and start to increasing
the last one year since 1990 from 425 per 100,000 population per year and
reached a peak value of 482 per 100,000 population per year in 1994. Since
1995 onwards however, the estimates for TB prevalence rate have shown a
steady decline at an average rate of 4 percent per year, with an increased rate
of decline for the last 5 years (5.5 percent per year) and reached a level of
154/100,000 population and increased rate 30 percent for the last year that
reached a level of 200/100,000 population.
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Figure 2.2: Number of notified TB cases in Ethiopia (1996-2014).
The above figure shows that the number of TB cases has been steadily in-
creasing since 1996 from 79,095 to reach a peak of 159,017 cases in 2011.
However; the number of notified TB cases has shown a marked decline over
the last three successive years and reach a level of 115,821 cases in 2014 which
as shown in this figure.
According to the Federal Democratic republic of Ethiopia Ministry of Health,
the documented MDR-TB patients for years shown below [26, 29, 58].
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Figure 2.3: The trend of notified MDR-TB for three successive years.
In the view of the above discussion, we develop and analyze a mathematical
model (2.2.1) below describing the dynamics of TB with age of infection. This
model accounts for the data obtained from the Federal Democratic Republic
of Ethiopia Ministry of Health, in particular, from Health Promotion and
Diseases Prevention Directorate, Ministry of Health Directorate and Police
Planning Offices. The data indicated that both drug sensitive TB and drug
resistant TB strains did recover in Ethiopia. Epidemiological modeling led
to the analysis of ordinary differential, discrete/stochastic/ or partial differ-
ential systems. Age-structured models comprise partial differential equations
models whose dynamics depend on whether the age of the population and
the age of infection are taken to account or not.
We show that the stability of the system equilibria is completely determined
by the basic reproduction number of TB, RTB. The system is shown to
exhibit the existence of a disease free and the endemic equilibria.
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2.2 Description of a TB model with age of
infection
The total population in our model is divided into three epidemiological classes
SIS-model according to their diseases status as in [73]: Susceptible class
ST (t), infectious class with drug sensitive strain Is(t) and infectious class
with drug resistant strain Ir(t). Susceptible individuals are recruited into the
population at a contact rate c. These individuals are infected with the force
of infections λs and λr respectively for drug sensitive and drug resistant TB
and due to their contact with active TB. Drug sensitive and resistant strains
were modeled, but only the age of the infection with drug sensitive strain
was considered [9, 73].
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The flow diagram is expressed as:
Figure 2.4: Flow diagram of the SIS compartments of the TB with treatment
model.
Letting is(α, t) be the infection density of infected individuals of age α with
the drug sensitive strain at the current time t, the model framework indicates
the following system of nonlinear ordinary and partial differential equations:
dST
dt
= Λ− (λs + λr + µ)ST + ηIr + (1− r)θIas ,
∂is
∂α
(α, t) + ∂is
∂t
(α, t) = −((1− r + qr)p(α)θ + µ+ ds)is(α, t)
dIr
dt
= λrST − (dr + µ+ η)Ir + qrθIas
(2.2.1)
where, Ias =
∮∞
0
p(α)is(α, t)dα is the total number of active TB with drug
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sensitive strain. These are infected individals individuals with the strain
that can transmit the disease only to others at the age of their infection.
Is(t) =
∮∞
0
is(α, t)dα is the total number of infected individuals with drug
sensitive TB. These include the infectious individuals that transmit the dis-
ease (active TB) and the latent individuals that do not transmit it. Here,
as already pointed in the introduction most of the infected individuals with
drug-sensitive TB remains latent, but only a small portion of them develop
and show the disease, becoming infective. To account for this, we assume the
function p(α) ( 0 ≤ p(α) ≤ 1 ) as the proportion of sensitive -strain-infected
individuals which are active at infection-age α. In the case of drug resistant
TB, it accounts for active TB only. Other related parameters are defined as
follows: λs = βsc
Is
NT
is the force of infection of drug sensitive TB,
λr = βrc
Ir
NT
is the force of infection of drug resistant TB,
c=per-capita contact rate,
θ=per-capita TB treatment rates for infected(infectious),
βs =the probability that a susceptible individual becomes infected by one
infectious individual with drug sensitive,
βr =the probability that a susceptible individual becomes infected by one
infectious individual with drug resistant TB,
ds= The disease induced mortalities for drug-sensitive,
dr=the disease induced mortalities drug-resistant TB.
It is assumed that a fraction r of the treated individuals with drug-sensitive
strain does not recover due to incomplete treatment, and the remaining (1−r)
is successfully treated and become susceptible again. It is also assumed that
a fraction q of those who do not finish their treatment will generate drug re-
sistant TB and the remaining fraction (1− q) of them will keep as infectious.
The data obtained from ministry of health in Ethiopia indicated that drug
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resistant TB strains were cured and then treated like drug-sensitive strain TB
[23, 26, 28]. Therefore, according to our assumptions the cured strains be-
come susceptible again. Hence we introduce that η is the fraction of treated
individuals with drug resistant TB that is cured and becomes susceptible
again and that the remaining fraction (1 − η) does not recover nor become
latent since individuals who are not cured die after acquiring drug resistant
TB. The total population considered for this compartment model is given by
NT = ST + Ir +
∮ ∞
0
is(α, t)dα = ST + Ir + Is (2.2.2)
The following table gives the values of the parameters used in our analysis.
ST (0) = 178, 445, Ethiopia total population=87,989,000.
Symbol Value Sources
Λ 33.3/1000[46, 56, 59]
µ 0.0165 [46, 56, 59]
c 0.7 [32, 69]
(1− r) 0.921 [26, 56]
βs 0.653 [26, 46, 58]
ds 0.024 [58, 59]
q 0.270 [26, 58, 59]
η 0.178 [26]
βr 0.013 [26, 46, 59]
dr 0.011 [26, 58]
Table 2.2: The values of the parameters used in the system (2.2.1) [12, 13,
48].
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2.3 A Well-posed problem
2.3.1 Definition: (Well-posed problem)
A mathematical problem is said to be a well-posed problem if its solution
exits, is unique and depends continuously on the data, initial conditions on
the (finite) boundary of the domain.
The other most important concepts in epidemiological models is the basic
reproduction number (R) for a given parasite strain that is defined below.
2.3.2 Definition: (Basic reproduction number)
The basic reproduction number is defined as the expected number of new in-
fections from one infected individual in a fully susceptible population through
the entire duration of the infectious period. If R < 1, then on average an
infected individual produces less than one new infected individual over the
course of its infectious period, and the infection cannot grow. Conversely, if
R > 1, then each infected individual produces, on average, more than one
new infection, and the disease can invade the population in [1, 32, 37, 39, 43,
51].
We can now move to the mathematical analysis of the model.
2.4 Analysis of the model
In this section, we discuss the mathematical analysis of the TB model given in
the systems (2.2.1) to show the stability equilibria of the system according to
the basic reproduction number we computed. We determine all these things
first by considering the models well-posed and its positivity of solutions.
In this analysis, we consider the drug resistant only sub-model when Is = 0.
31
This is done in the following section.
2.4.1 Analysis of drug resistant TB only sub-model
Here, we highlighted the drug resistant TB sub-model with simple concepts
but more details are shown in the next subsection. when Is = 0, the systems
of equations (2.2.1) reduces to:
dST
dt
= Λ− (λr + µ)ST + ηIr,
dIr
dt
= λrST − (η + dr + µ)Ir.
(2.4.1)
where, NT = ST + Ir which implies that ST = NT − Ir.
Hence we have
dNT
dt
= Λ− µNT − drIr,
dIr
dt
= βrc(1− IrNr )Ir − (µ+ dr + η)Ir
(2.4.2)
For this system of equation, by applying the next generation matrix approach
[82], where F and V are represented as matrices respectively for the new
infections generated and the transition terms is then obtained as,
z = βrcIr and
ϑ = (µ+ dr + η)Ir.
Here, F = (βrc) and
V = (µ+ dr + η).
Rr, the basic reproduction number of drug resistant TB only sub-model is
given by spectral radius, ρ of FV −1, i e Rr = ρ(FV −1) =
βrc
(µ+dr+η)
.
Before showing the proofs of the theorems stated below, it it better to recall
Routh Hurwitz Criteria [86] are used to determine local asymptotic stability
of an equilibrium for nonlinear systems of differential equations. The Routh-
Hurwitz Criteria are stated in the next theorem.
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Theorem 2.4.1. ([86]) Routh-Hurwitz Criteria. Given the polynomial,
P (λ) = λn + a1λ
n−1 + a2λn−2 + ...+ an−1λ+ an,
where the coefficients ai are real constants, i = 1, 2, ..., n, define the n Hur-
witz matrices using the coefficients ai of the characteristic polynomial:
H1 =
(
a1
)
,
H2 =
 a1 1
a3 a2
 ,
H3 =

a1 1 0
a3 a2 a1
a5 a4 a3
 ,

a1 1 0 0 . . . 0
a3 a2 a1 1 . . . 0
a5 a4 a3 a2 . . . 0
a7 a6 a5 a4 . . . 0
. . . . . . . .
. . . . . . . .
. . . . . . . .
0 0 0 0 . . . an

,
where aj = 0 if j > n. All of the roots of the polynomial P (λ) are negative or
have negative real part if and only if the determinants of all Hurwitz matrices
are positive:
detHj > 0, j = 1, 2, ..., n.
When n = 2, the Routh-Hurwitz criteria simplify to
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detH2 = det
 a1 1
0 a2
 = a1a2 > 0 or a1 > 0 and a2 > 0.
For polynomial of degree n = 2, 3, 4 and 5, the Routh-Hurwitz criteria are
summarized as shown below.
For
n = 2 : a1 > 0 and a2 > 0.
n = 3 : a1 > 0, a2 > 0 and a1a2 > a3.
n = 4 : a1 > 0, a2 > 0, a3 > 0, a4 > 0 and a1a2a3 > a
2
3 + a
2
1a4.
n = 5 : ai > 0, i = 1, 2, 3, 4, 5, a1a2a3 > a
2
3 + a
2
1a4, and
(a1a4 − a5)(a1a2a3 − a23 − a21a4) > a5(a1a2 − a3)2 + a1a25.
Proof. For n = 2, the Routh-Hurwitz criteria are just a1 > 0 and a2 > 0.
The characteristic polynomial in the case n = 2 is
P (λ) = λ2 + a1λ+ a2.
The eigenvalues satisfy
λ1,2 =
−a1±
√
a21−4a2
2
.
Suppose a1 and a2 are positive, it is easy to see that if the roots are real, they
are both negative, and if they are complex conjugates, they have negative
real part.
Next, to prove the converse, suppose the roots are either negative or have
negative real part. Then it follows that a1 > 0. If the roots are complex
conjugates, 0 < a21 < 4a2, which implies that a2 is also positive. If the roots
are real, then since both of the roots are negative it follows that a2 > 0.
Corollary 2.4.2. Suppose the coefficients of the characteristic polynomial
are real. If all of the roots of the characteristic polynomial
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P (λ) = λn + a1λ
n−1 + a2λn−2 + ...+ an−1λ+ an,
are negative or have negative real part, then the coefficients ai > 0 for i =
1, 2, ..., n.
Proof. The corollary is a direct consequence of the Routh-Hurwitz criteria
but can be verified separately. The characteristic equation can be factored
into the form
(λ+ r1)...(λ+ rk1)(λ
2 + 2c1λ+ c
2
1 + d
2
1)...(λ
2 + 2ck2λ+ c
2
k2
+ d2k2) = 0,
where the roots are −ri < 0 for i = 1, 2, ..., k1 and the complex roots are
cj ± dj for j = 1, 2, ..., k2 and k1 + k2 = n. If all the roots are either negative
or have negative real part, then ri > 0 and cj > 0 for all i and j. Thus the
coefficients in the factored characteristic equation are positive.
The disease free equilibrium of the system in (2.4.1) is given by E0 =
(Λ
µ
, 0) is locally asymptotically stable if Rr < 1 and otherwise unstable if
Rr > 1.
By considering the following theorems, we investigate whether the system
(2.4.1) is stable or not.
Theorem 2.4.3. ([32, 66]) Drug resistant TB dies out whenever Rr < 1
and persists whenever Rr > 1.
Proof. By substituting the disease free equilibrium of the system in (2.4.1)
and using next generation matrix methods [82] for:
z = βrcIr
and ϑ =
 βrc IrNT Ir + (µ+ dr + η)Ir
µNT + drIr
 .
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We obtained F = (βrc),
V = (µ+ dr + η),
Rr = ρ(FV
−1) = βrc
(µ+η)+dr
.
We found the corresponding Jacobian matrix as follows:
J(E0) =
 −µ −dr
0 βrc− (µ+ η + dr)

.
Hence, the eigenvalues of the matrix are:
λ1 = −µ,
λ2 = βrc(1− 1Rr ).
Thus, the first eigenvalue, λ1 is always negative. The second eigenvalue, λ2
is negative if Rr < 1 and is positive if Rr > 1.
Hence, the disease free equilibria is stable if Rr < 1 and unstable if Rr > 1.
Thus , this completes the proof this theorem. Similarly, the endemic equi-
librium theorem stated as follows.
Theorem 2.4.4. ([32]) The endemic equilibrium of drug resistant TB is
locally asymptotically stable if Rr > 1 and it is unstable if Rr < 1.
Proof. We can denote the endemic equilibrium of the system in (2.4.1) as
E1 = (N1T , I
1
r ) is given by
E1 = ( Λ
µ+dr(1− 1Rr )
,
Λ(1− 1
Rr
)
µ+dr(1− 1Rr )
)
Then its corresponding Jacobian matrices becomes
J(E1) =
 −µ −dr
βrc(1− 1Rr )2 −βrc(1− 1Rr )

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.The characteristic equation associated with the above matrix is given by
λ2 + C1λ+ C2 = 0.
Where,
C1 = µ+ βrc(1− 1Rr ),
C2 = µβrc(1− 1Rr ) + βrcdr(1− 1Rr )2.
As we observed the coefficients C1 and C2 are both greater than zero if
Rr > 1. And all the roots of the above characteristic equations are negatives
or have negative real parts. Hence using these results and Routh Hurwitz
Criteria:
• When λ = −1, 1− C1 + C2 > 0,
1 + C2 > C1,
• When λ = 1, 1 + C1 + C2 > 0,
• When λ = 0, |C2| < 1.
Therefore, the endemic equilibrium is locally asymptotical stable if Rr > 1,
and unstable if Rr < 1.
2.4.2 Analysis of the full TB model
In this section, we discuss some of the highlights of the mathematical analysis
of the TB model given in the systems of equations (2.2.1) to show positivity
of solution, its existence of invariant set and the stability equilibria of the
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system according to the basic reproduction number we computed.
To find the basic reproduction number of our model, first we rewrite the
systems in (2.2.1) as a linear form and integrate both sides of the second
equation using a Cauchy problem and compatibility condition in the system
along the characteristics line t− α=constant. After we linearize the system
we can easily find the basic reproduction number as defined in different lit-
eratures.
The density age function which is given in (2.2.1) recalled as follows:
∂is
∂α
(α, t) +
∂is
∂t
(α, t) = −((1− r + qr)p(α)θ + µ+ ds)is(α, t) (2.4.3)
subject to the initial condition is(0, t) = λsST (t). This is the PDE that has
the cauchy problem form, can be solved by considering the rate of change
of is(α, t) with arbitrary variable parameter-σ as we move along this curve
has the form dis
dσ
= ∂is
∂α
+ ∂is
∂t
and is equivalent to the equation in (2.4.3) at
point (α, t) below, which is the solution of a quasi-linear first order partial
differential equation involving unknown function is(α, t). Consequently it is
only necessary to consider the solution of a Cauchy problem for quasi-linear
equations that is written in the form:
U(α, t, is)
∂is
∂α
+ V (α, t, is)
∂is
∂t
= f(α, t, is) (2.4.4)
,
where U, V and f are assumed to be continuously differentiable functions of
their arguments.
Let is(σ) = is(σ, α(σ), t(α)), the total derivative of is(α, t) in terms of arbi-
trary variable parameter-σ is
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dis
dσ
=
∂is
∂α
dα
dσ
+
∂is
∂t
dt
dσ
(2.4.5)
From equations of (2.4.4) and (2.4.5) above, we have the following:
dα
dσ
= U(α, t, is)and
dt
dσ
= V (α, t, is) (2.4.6)
The PDE in (2.4.4) can be expressed as the ODE dis
dσ
= f(α, t, is) provided
that α and t satisfy (2.4.6) with respect to σ.
From the equations (2.4.4) to(2.4.6) in the above, we have
is(α, t) = λs(t)ST (t)e
−(µ+ds)α−
∮ α
0 δ(s)ds,
where, δ(s) = (1−r+qr)θp(s) is obtained from the initial value in the system
(2.2.1).
By letting λs(t)ST (t) = m(t) and considering the initial conditions of the
above PDE, we have:
iso(0, t) = λs(t)ST (t) = m(t)
iso(α, 0) = iso(α)
(2.4.7)
Therefore, we have
is(α, t) =
m(t− α)e−(µ+ds)α−
∮ α
0 δ(s)ds, for t > α,
iso(α− t)e−(µ+ds)α−
∮ α
α−t δ(s)ds, for α > t.
(2.4.8)
From equation (2.4.8), we computed that limt→∞ is(α, t) = 0, since the func-
tion of α and t is non-increasing as observed above.
And again by integrating both sides of (2.4.3) with respect to α, we obtained
dIs
dt
= λs(t)ST (t)− (µ+ ds)Is −
∮ t
0
m(t− α)p(α)e−(µ+ds)α−
∮ α
0 δ(s)dsdα
(2.4.9)
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After obtaining the derivatives of m(t) in equations (2.4.7) and according to
[73], we have:
dm
dt
=
βsc
NT
(NT − Ir −
∮ t
0
m(t− α)p(α)
∮ t
0
p1(α)m(t− α)p2(α) = m(t)
(2.4.10)
where, the notations,
p1 =
∮ t
0
e−(µ+ds)α−
∮ α
0 δ(s)dsdα,
p2 =
∮ t
0
p(α)e−(µ+ds)α−
∮ α
0 δ(s)dsdα.
Here we can get p2m =
∮∞
0
p2(α)m(t− α)dα.
Let us consider the equilibrium at E∗(N∗T ,m
∗, I∗r ) at α = 0 and when it
exists , must be constant solution of the limiting system associated with it,
thus from (2.4.10) and (2.2.1 ), the system of equations reduced to
dNT
dt
= Λ− µNT − drIr − ds
∮ t
0
m(t− α)e−(µ+ds)α−
∮ α
0 δ(s)dsdα,
dm
dt
= βsc(1− p1NTm− IrNt )p2m,
dIr
dt
= βrc(1− p1NTm− IrNt )Ir − (µ+ η + dr)Ir + qrθp2m.
(2.4.11)
By taking the of the above system, we search for solutions at equilibrium
(N∗T ,m
∗, I∗r ) of the system,
Λ− µN∗T − drI∗r − dsp1m∗ = 0,
βsc(1− p1N∗Tm
∗ − I∗r
N∗t
)p2m
∗ = m∗,
βrc(1− p1N∗Tm
∗ − I∗r
N∗t
)I∗r − (µ+ η + dr)I∗r + qrθp2m∗ = 0.
(2.4.12)
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The solutions of the systems are related to the distribution of infected indi-
viduals with drug-sensitive TB at the steady state as
iso(α, 0) = iso(α) = p1m
∗.
Moreover, when we take Ir = 0 (the infected individuals do not develop drug-
resistant TB, i.eq = 0). Thus, particularly, the above system of equations
(2.4.12) becomes the mathematical model of drug-sensitive TB as follows:
Λ− µN∗T − dsp1m∗ = 0,
βsc(1− p1N∗Tm
∗)p2m∗ = m∗.
(2.4.13)
Hence from the systems equations (2.2.1) and (2.4.12), using next generation
matrix methods [82] for:
z = βscp2m∗ and ϑ = m∗, we obtained F = (βsc)p2,
V = 1,
Rs = ρ(FV
−1) = (βsc)p2 (the basic reproduction number of with drug-
sensitive TB). In addition to this by solving the equations, we obtained the
endemic equilibrium of drug-sensitive TB, denoted as E∗ = (N∗T ,m
∗) as
shown below:
m∗ =
N∗T (1− 1Rs )
p1
,
N∗T =
Λ
µ+ds(1− 1Rs )
.
Theorem 2.4.5. ([32, 66, 73]) Drug-sensitive TB dies out whenever Rs < 1
and persists whenever Rs > 1 given that q = 0.
Proof. By substituting the disease free equilibrium of the drug-sensitive sys-
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tem in (2.2.1) and (2.4.12), we found the corresponding Jacobian matrix as
follows:
J(E0) =
 −µ −dsp1
0 βscp2 − 1

.
Hence, the eigenvalues of the matrix are:
λ1 = −µ,
λ2 = βscp2(1− 1Rs ).
Thus, the first eigenvalue, λ1 is always negative. The second eigenvalue, λ2
is negative if Rs < 1 and is positive if Rs > 1.
Hence, the disease free equilibrium of drug-sensitive TB dies out if Rs < 1
and persists if Rs > 1.
Similarly, the endemic equilibrium theorem stated as follows.
Theorem 2.4.6. ([32]) The endemic equilibrium of drug-sensitive TB is
locally asymptotically stable if Rs > 1 and it is unstable if Rs < 1.
Proof. The proof of this theorem is direct since we obtained the endemic
equilibrium as shown above.
Hence,
Rs = βscp2 = βsc
∮∞
0
p(α)e−(µ+ds)α−
∮ α
0 δ(s)dsdα
and
Rr =
βrc
µ+η+dr
are the basic reproduction number of drug sensitive and drug-resistant TB
of the system (2.2.1), respectively.
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Therefore, for the total population, the basic reproduction number of TB of
the model (2.2.1), denoted by RTB, is given by RTB = max(Rs, Rr).
Rs is the product of the probability of a susceptible individual infected by
one infectious individual with drug sensitive TB during his or her contact
βsc and the total active drug-sensitive TB.
Rr is the product of the probability of susceptible individual infected by one
drug-resistant TB infectious individual βrc and the average infectious period
1
µ+dr+η
.
Therefore, Rs measures the number of secondary drug-sensitive TB infec-
tious cases produced by a TB infectious individuals during his or her effec-
tive contact when introduced in a susceptible population of TB. Similarly Rr
gives the number of secondary drug-resistant TB infectious cases produced
by TB infectious due to incomplete treatment of drug-sensitive TB individ-
uals during his or her infectious period when introduced in a population of
TB susceptible.
In the next section, we consider positivity of solutions and existence of in-
variant set model (2.2.1).
2.4.3 Positivity of solutions and existence of invariant
set
Most delay differential equations that arise in population dynamics and epi-
demiology models logically have nonnegative quantities. It is important to
establish that nonnegative initial data give rise to nonnegative solutions. The
model system (2.2.1) above describes the dynamics of a human population.
Therefore, it is important to prove that the state variables susceptible ST (t),
infectious with drug sensitive Is(t), and drug-resistant TB Ir(t), are non-
negative for all time t ≥ 0. For this, we state and prove the next theorems.
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Theorem 2.4.7. The feasible region in the set D = {(ST , is, Ir)R3/NT ≤ Λµ}
is positively-invariant for system (2.2.1).
Proof. The rate of change of the total population computed from the equa-
tions of models (2.2.1), (2.2.2) and the first equation of (2.4.11) is given by
dNT
dt
= Λ− µNT − drIr − ds
∮ t
0
m(t− α)p1(α)dα ≤ Λ− µNT . (2.4.14)
Where, p1 = e
−(µ+ds)α−
∮ α
0 δ(s)ds.
Which shows the feasible region D = {(ST (t), is(α, t), Ir(t))R3/(ST (t) +∮∞
0
is(α, t)dα+ Ir(t) = NT ≤ Λµ} and we observed that lim supt→∞NT ≤ Λµ}.
It is clear that dNT
dt
≤ Λ
µ
, since NT (0) ≤ Λµ .
And also from equation (2.2.1) and equation (2.3.2.8), we find that
dS
dt
= Λ− (λs + λr + µ)ST + (1− r)θIas + qrηθIas ≥ (λs + λr + µ)ST ,
which implies that ST (t) ≥ ST (0)e−(λs+λr+µ)t , for all t ≥ 0.
Similarly; Is(t) ≥ Is(0)e−(µ+ds)t for all t ≥ 0.
Ir(t) ≥ Ir(0)e−(µ+dr)t for all t ≥ 0.
Thus, all the above shows that the solution of the system (2.2.1) is greater
or equal to zero for all t ≥ 0.
Therefore, the limits of the system in (2.2.1) with initial conditions remain
in D and all the variables and parameters of it are non-negative for all t ≥ 0.
Hence, D is positivity of invariant. And the mathematical model in (2.2.1)
in the region D is epidemiologically well-posed.
In the next section, we study the equilibria and stability properties of our
model in (2.2.1).
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2.4.4 Stability properties of the equilibria
In this section, we find the equilibria and determine the stability properties
of the epidemiology model in (2.2.1). The details of the disease free and the
endemic equilibria of the system (2.2.1) are shown in the following theorems
(2.4.8) and (2.4.9) as stated.
Theorem 2.4.8. ([65, 66, 73]) The disease free equilibrium of both drug sen-
sitive and drug resistant TB die out (locally asymptotically stable) whenever
RTB < 1 and persist whenever RTB > 1.
Proof. The disease free equilibrium, denoted by E0 of the system (2.2.1) is
E∗ = (Λ
µ
, 0, 0).
By substituting this to the system (2.2.1), we obtained the corresponding
Jacobian matrix as follows:
J(E∗) =

−µ −dsp1 −dr
0 p2βsc− 1 0
0 qrθp2 βrc− µ− η − dr

.
Thus, the eigenvalues of the matrix are:
λ1 = −µ,
λ2 = p2βsc− 1 = Rs − 1 ,
λ3 = βrc− µ− dr = (µ+ η + dr)(Rr − 1).
Hence, the first eigenvalue, λ1 is always negative.
The second and third eigenvalues, λ2 and λ3 are negatives when both Rs and
Rr are less than one , respectively. Otherwise they are positive if both Rs
and Rr are greater than one.
Using Rouths stability criterion [84-86], we have RTB = max(Rs, Rr) < 1
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while all eigenvalues are negatives.
Therefore, the disease free equilibrium is locally asymptotically stable if
RTB < 1 and unstable if RTB > 1.
The following theorem shows the stability of endemic equilibria of our model.
Theorem 2.4.9. ([32, 65, 66, 73]) The endemic equilibrium of the epidemic
model (2.2.1) is locally asymptotically stable whenever RTB > 1 and it is
unstable whenever RTB < 1.
Proof. In our previous sections we had shown the endemic properties of drug-
resistant TB while no drug-sensitive TB and vice versa. So showing when
both TB strains are endemic is enough consideration of this case.
The endemic equilibrium denoted by E∗ = (N∗T ,m
∗, I∗r ) of the model (2.2.1),
which was further expressed and rewritten as in the system (2.4.12) solved
below to investigate whether Rs > 1 and Rr < 1 or Rs < 1 and Rr > 1 or
Rs > 1 and Rr > 1.
we obtained:
N∗T =
Λ
µ+dsχ+
dr(1− 1Rs )
1+χ
,
m∗ =
Λχ(1− 1
Rs
)
µ+dsχ+
dr(1− 1Rs )
1+χ
= N∗Tχ
(1− 1
Rs
)
(1+χ)p1
,
I∗r =
Λ(1− 1
Rs
)
(µ+dsχ+
dr(1− 1Rs )
1+χ
)(1+χ)
= N∗T
(1− 1
Rs
)
(1+χ)
.
Where,
χ =
p1(µ+η+dr)(1−RrRs )
qrθp2
. However, when we checked the positivity of our so-
lutions, we found the relationships of the basic reproduction numbers and
other constants as follows:
• χ > 0 implies that (1− Rr
Rs
) > 0 as a result Rs > Rr.
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• The endemic equilibrium is positive when both χ > 0 and (1− 1
Rs
) > 0,
which is equivalent to Rs > 1.
As we did the endemic equilibrium of drug-sensitive TB above (i.e when
Ir = 0), it is true if there is no infected individuals who develop drug-
resistant TB which is q = 0. But here, it is not the case we consider in
our purpose. Therefore, from the these cases and with generally truth, our
model is endemic at the endemic equilibrium when both Rs and Rr greater
than one since Rs > 1 and Rs > Rr.
2.5 Numerical results and simulations
In this section, we perform some numerical simulations in order to study
the epidemiology model of the system (2.2.1). For our purpose we take the
values of the parameters from the table 2.2.1 and the prevalence, incidence
and notifications of drug-sensitive and MDR-TB considered in above sections.
In the following sections, we consider the numerical simulations at the disease
free and endemic equilibria.
2.5.1 The numerical simulations at the disease free
equilibria
In the figures (2.5) and (2.6) below, the first two figures showed solutions of
susceptible to TB on the left side and infected individual with drug-sensitive
TB on the right side. But the last one shows the solution of infected indi-
viduals with drug-resistant TB of the disease free equilibrium of the model
(2.2.1) at different initial values when RTB < 1.
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Figure 2.5: These are solutions of TB model with initial solutions
(S(0), Is(0), Ir(0)) = (178000, 40, 5).
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Figure 2.6: These are solutions of TB model with initial solutions
(S(0), Is(0), Ir(0)) = (130000, 48400, 45).
2.5.2 The numerical simulations at endemic equilibria
Here, we discuss solutions of the endemic equilibrium of the model (2.2.1) at
different initial values when RTB > 1. The numerical simulations as shown in
the following figures (2.7, 2.8 and 2.9), first two figures showed solutions of
susceptible to TB on the left side and infected individual with drug-sensitive
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TB on the right side. But the last one shows the solution of infected indi-
viduals with drug-resistant TB in all cases.
Figure 2.7: These are solutions of TB model with initial solutions
(S(0), Is(0), Ir(0)) = (100000, 70000, 8445).
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Figure 2.8: These are solutions of TB model with initial solutions
(S(0), Is(0), Ir(0)) = (100000, 70000, 2000).
The following figure shows the region of equilibria stability of TB models
discussed in our previous sections .
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Figure 2.9: Basic reproduction number of drug-sensitive TB.
This figure shows the region of unstable disease free equilibrium and stable
endemic equilibrium points lie when the basic reproduction number greater
than unity, but the stable disease free equilibrium and unstable endemic
equilibrium lie in the region when the basic reproduction number less than
unity.
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Chapter 3
Description of the HIV-TB
co-infection model
We develop and analyze a mathematical model describing the dynamics of
HIV-TB co-infection. In this model, the dynamics of both drug-sensitive and
resistant strains TB discussed in chapter two and HIV are considered. It is
the combination of the model presented in chapter 2 and the HIV model
presents in this chapter. We develop and analyze a mathematical model
describing the dynamics of HIV-TB co-infection. In this model, the dynamics
of both drug-sensitive and resistant strains TB discussed in chapter two and
HIV are considered. It is the combination of the model presented in chapter
2 and the HIV model presents in this chapter.
3.1 Introduction
In recent history, the paths of HIV and Tuberculosis have come to a critical
intersection. Combined, these two diseases are the leading cause of mortality
due to infectious disease [71]. In Sub Saharan African countries including
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Ethiopia, there were 24.7 million people living with HIV and 1.1 million
people died from AIDS-related causes in 2013 (UNAIDS, Fact sheet 2014).
In 2013, the worldwide percentage of identified HIV-positive tuberculosis
patients who started or continued the anti-retro-viral treatment reached 70
percent (up from 60 percent in 2012) [55, 59, 64].
It is estimated that one third of the worlds population is host to tuberculosis
and among the estimated 9 million people who developed TB, an estimated
1.1 million (13 percent) were HIV positive. There were also 360,000 deaths
from HIV associated TB equivalent to 25 percent of all TB deaths, and
around 25 percent of the estimated 1.5 million deaths from HIV/AIDS in
2013 [59].
What links these two diseases so intimately is their common substrate of
poverty; both are concentrated in resource-limited areas, exposing the social
determinants of the diseases [69, 71]. Despite the fact that these diseases
remain rampant in developing countries like Ethiopia, a lack of resources
dedicated to co-infection has resulted in little progress being made at their
intersection [55-68].
In the year 2012, the total number of new TB cases detected by TB DOST
(Directly Observed Treatment, Short-Course ) program represents a popula-
tion of 92531. The data also described that 46869 of them were the number
of new smear positive pulmonary TB cases detected by the program. In
the same year, there were 74048 TB patients enrolled in DOST and tested
for HIV in the quarter. From those population 9280 number of TB patients
were co-infected with HIV (enrolled in DOTS who were HIV positive). In the
year 2012, a total of 5641830 clients received HIV test and from them 81415
clients were testing positive for HIV. The number of PLWHA ever enrolled
in HIV care who ever started the ART and who are currently receiving ART
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were 432232, 244454 and 183249 respectively [21, 22, 29, 30].
HIV infection and infection with TB bacteria are though completely differ-
ent infections. If you have HIV infection you will not be infected with TB
bacteria unless you are in contact with someone who also is infected with
TB bacteria. Although if you live in a country with a high prevalence of TB
this may have happened without you realize it. Similarly if you have TB you
will not be infected with HIV unless you carry out an activity with someone
who already has HIV infection, which results in you getting the HIV from
them. TB also occurs earlier in the course of HIV infection than many other
opportunistic infections. The risk of death in co-infected individuals is also
twice that of HIV infected individuals without TB, even when CD4 cell count
and antiretroviral therapy are taken into account [69].
The figures and tables presented in the previous chapters showed the preva-
lence and incidence of TB as well as HIV-TB co-infection in Ethiopia. Ac-
cording to the best of our knowledge discussed at the general introduction of
first chapter, we could hardly find research on mathematical modeling of HIV
and TB co-infections that incorporate TB treatment in nonlinear ordinary
and partial differential equations models. But from biological and medical
perspectives, the reader who wishes to have more information on HIV and
TB co-infections may consult the following works and also the references
there in [14, 19, 31, 32, 34, 36, 38, 39, 43, 44, 45, 51, 50, 56]. Therefore, we
will provide some concepts and models that fills these gaps in the following
sections.
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3.2 Formulation of HIV-sub model
Before we combine the models considered in this chapter, we first consider
the HIV only sub model. The total population divided into S susceptible
individuals, IH HIV infectious individuals in the SI model.
.
dS
dt
= Λ− λHS − µS
dIH
dt
= λHS − (µ+ dH)IH
(3.2.1)
dH =per-capita HIV-induced death rate.
βH= probability of HIV infection per contact with a person who is HIV in-
fectious and c is the per-capita contact rate for HIV,
λH = cβH
IH
N
-the force of infection.
The above model is also expressed using diagram as follows:
Figure 3.1: Flow diagram of the SI compartments of the HIV model.
56
Symbol Value Sources
βH 0.28 [26]
dH 0.05 [26]
Table 3.1: The values of the parameters used in (3.2.1)
The well-posed and positivity solution of this model is similar as we discussed
in the previous chapter. In the next sections, we discuss the stability and
epidemic equilibria of the the systems in (3.2.1).
3.2.1 Analysis of HIV sub-model
In this section, we discuss some of the points of mathematical analysis of
the HIV sub-model given in the systems of equations (3.2.1) to obtain the
basic reproduction number and to show the stability and unstably of the
equilibria and epidemic of the system according to the basic reproduction
number computed. The problems considered in our analysis are well-posed
problem as observed in the second chapter and viewed in different literatures
[32, 37, 39, 71].
3.2.2 Basic reproduction number
Recall that the basic reproduction number is defined as the expected number
of new HIV infections from one infected individual in a fully susceptible pop-
ulation through the entire duration of the infectious period. If RH < 1, then
an infected individual produces, on average, less than one new infected indi-
vidual over the course of its infectious period, and the infection cannot grow.
Conversely, if RH > 1, then each infected individual produces, on average,
more than one new infection, and the disease can invade the population as
we saw in the second chapter. By rearranging and substituting S in terms
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of N (S = N − IH)and IH into the system in (3.2.1), we obtained
dN
dt
= Λ− µN − dHIH
dIH
dt
= cβH
IH
N
(N − IH)− (µ+ dH)IH
(3.2.2)
For this system of equation, by applying the next generation method ap-
proach [82], F and V are represented as matrices respectively for the new
infections generated and the transition terms is then obtained as,
z = βHcIH and
ϑ = (µ+ dH)IH .
Here, F = (βHc) and
V = (µ+ dH).
RH , the basic reproduction number of HIV only sub-model is given by spec-
tral radius, ρ of FV −1, i e RH = ρ(FV −1) =
βHc
µ+dH
.
3.2.3 Positivity of solutions and existence of invariant
set
Most delay differential equations that arise in population dynamics and epi-
demiology model intrinsically nonnegative quantities. It is important to es-
tablish that nonnegative initial data give rise to nonnegative solutions. The
model system (3.2.1) above describes the dynamics of a human population.
Therefore; it is important to prove that the state variables susceptible S(t),
and IH(t), HIV infected individuals are non-negative for all time t ≥ 0.
For this, we state and prove the following proportion.
Theorem 3.2.1. The feasible region in the set D = {(S, IH)R2/N ≤ Λµ} is
positivity-invariant for system (3.2.1).
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Proof. The proof of this theorem is the same as the theorem 2.4.7 proved in
the previous chapter.
3.2.4 Stability and equilibria properties of HIV
In this section, we find the equilibria and determine the stability properties
of our model in (3.2.1).
Theorem 3.2.2. The disease free equilibrium of HIV in (3.2.1) is locally
asymptotically stable (will die out) if RH < 1 while it is unstable if RH > 1.
Proof. By substituting the disease free equilibrium of the system in (3.2.1)
is given by E0 = (Λ
µ
, 0) and using next generation matrix methods [82] for:
z = βHcIH
and ϑ =
 βHc IHNT IH + (µ+ dH)IH
µNT + dHIH
 .
By taking their partial derivatives with respect to the given variables, we
obtained
F = (βHc) and V = µ+ dH .
We also found the corresponding Jacobian matrix at the disease free equilib-
rium E0 = (N0, I0H) as follows:
J(E0) =
 −µ −dH
0 βHc− (µ+ dH)

.
Hence, the eigenvalues of the matrix are:
λ1 = −µ,
λ2 = βHc− (µ+ dH) = βHc(1− 1RH ).
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Thus, the first eigenvalue, λ1 is always negative. The second eigenvalue, λ2
is negative while RH < 1.
Hence, the disease free equilibria in the system (3.2.1) is locally asymptoti-
cally stable if RH < 1 while it is unstable if RH > 1.
Thus , this completes the proof this theorem. Similarly, the endemic equi-
librium theorem stated as follows.
Theorem 3.2.3. The endemic equilibrium of HIV in the system (3.2.1) is
locally asymptotical stable if RH > 1 and it is unstable whenever RH < 1.
Proof. : Here, we can denote the endemic equilibrium E1 = (N1, I1H) and
by solving (3.2.2), from the second equation we have I1H = (1− 1RH )N1. By
substituting this in the first equation of our system, we obtained
E1 = ( Λ
µ+dH(1− 1RH )
,
Λ(1− 1
RH
)
µ+dH(1− 1RH )
) and its corresponding Jacobian matrices as
J(E1) =
 −µ −dH
cβH(1− 1RH )2 −cβH(1− 1RH )

.
The characteristic equation associated with the above matrix is given by
λ2 + C1λ+ C2 = 0.
Where,
C1 = µ+ βHc(1− 1RH ),
C2 = µβHc(1− 1RH ) + βHcdH(1− 1RH )2.
As we observed the coefficients C1 and C2 are both greater than zero if
RH > 1. And all the roots of the above characteristic equations are neg-
atives or have negative real parts. Hence using these results and Routh
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Hurwitz Criteria [84, 85, 86]:
• When λ = −1, 1− C1 + C2 > 0,
1 + C2 > C1,
• When λ = 1, 1 + C1 + C2 > 0,
• When λ = 0, |C2| < 1.
Therefore, the epidemic equilibrium of the system (3.2.1) is locally asymp-
totical stable if Rr > 1, and it is unstable if Rr < 1.
By combining the above HIV sub-model (3.2.1) and models (2.2.1) in
chapter 2, we formulate the HIV-TB co-infection model in the following sec-
tion.
3.3 Formulation of HIV-TB co-infection model
In this model, we divide the total population into five sub-populations of SIS
epidemiological classes, Susceptible S(t), TB only infectious (i.e infectious
with drug sensitive strain Is(t) and infectious with drug resistant strain Ir(t),
HIV only infectious IH(t), and infectious with both HIV and TB, IHTB(t).
It is assumed that susceptible population are recruited into the population at
a constant rate Λ. They either acquire infection with TB following effective
contact with infected population (at rates λs and λr) and move to the TB in-
fectious class (Is(t) and Ir(t)) or acquire infection with HIV following effective
contact with infected population (at a rate λH) and move to the HIV infec-
tious class (IH(t)). Infected individuals with TB only are either successfully
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treated and move into susceptible class (at a rate (1 − r)θ + η) or acquire
infection with HIV following effective contact with infected population(at
rates σsλH and σrλH) for drug sensitive and drug resistant respectively. The
parameters 0 < σs ≤ 1 and 0 < σr ≤ 1 models the expected decrease in sex-
ual activity (contact) by individuals with TB infection (because of ill health)
[35, 51, 66] who move to the HIV-TB co-infectious class (IHTB). They die
from the disease (at rates ds and dr).
Infected individuals with HIV only either acquire infection with TB following
effective contact with infected individuals (at rates γsλs, γrλr) and move to
the HIV-TB co-infectious class (IHTB) or die from HIV (at a rate dH). Here
γs > 1 and γr > 1 accounts for the assumed increase in susceptibility to TB
infection (drug sensitive and resistant) as a result of HIV infection [45].
Co-infected individuals either recover with partial immunity and move into
HIV only infectious class (at a rate υ) or die from TB (drug sensitive and
drug resistant TB) (at rates κsds andκrdr). Here κs > 1; κr > 1 account for
the increased mortality of the IHTB individuals in comparison to individuals
with TB infection but not infected with HIV [45] or from HIV (at a rate
κhdH , κH > 1 accounts for the increased mortality of the IHTB individuals
in comparison to individuals with HIV infection but not infected with TB)
[17, 25, 45]. The death due to natural causes occurs in all population classes
at rate µ.
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The flow diagram is expressed as shown below:
Figure 3.2: Flow diagram of HIV-TB co-infection with TB treatment.
Using the flow diagram for their interconnection, the above assumptions and
notations, the HIV and TB co-infection with TB treatment model is written
as follows:
dS
dt
= Λ− (λs + λr + λH)S − µS + ηIr + (1− r)θIas
( ∂
∂t
+ ∂
∂α
)is(α, t) = −[((1− r + qr)θ + σsλH)p(α) + µ+ ds]is(α, t)
dIr
dt
= λrS − σrλHIr − (dr + µ+ η)Ir + qrθIas
dIH
dt
= λHS + υIHTB − (γsλs + γrλr)IH − (dH + µ)IH
dIHTB
dt
= σsλHI
a
s + σrλHIr + (γsλs + γrλr)IH − ωIHTB
(3.3.1)
where, is(0, t) = βscS
Ias
N
,
Ias (t) =
∮∞
0
p(α)is(α, t)dα, total number of active TB of drug-sensitive strain,
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Is(t) =
∮∞
0
is(α, t)dα, total number of infected individuals with TB of drug-
sensitive TB(both latent and active TB are included),
ω = µ+ ν + κsds + κrdr + κHdH .
3.4 Analysis of the HIV-TB co-infection model
In this section, we discuss some of the concepts of mathematical analysis of
the HIV-TB co-infection model given in the system of equations (3.3.1). The
aim is to obtain the basic reproduction number(s), to show the stability of
equilibria of the system according to the basic reproduction number.
3.4.1 Well-posed problem
The definition of well-posed problem and its properties considered in chapter
2 are also true here too. Therefore, in the next sections we consider the
stability, equilibria properties and numerical simulations of the model.
3.4.2 Basic reproduction number
By integrating the second equation with respect to α that runs between 0
and ∞ and expressing
dN
dt
=
dS
dt
+
dIs
dt
+
dIr
dt
+
dIH
dt
+
dIHTB
dt
(3.4.1)
We can also express S in terms of other variables as
S = N − Is − Ir − IH − IHTB.
Hence the system of equation in (3.3.1) can be rewritten as
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dN
dt
= Λ− µN − dsp1m− drIr − dHIH − dIHTB
dm
dt
= βsc(1− p1mN − IrN − IHN − IHTBN )p2m−m
dIr
dt
= βrc(1− p1mN − IrN − IHN − IHTBN )Ir−
(σrλH + µ+ dr + η)Ir + qrθp2m
dIH
dt
= βHc(1− p1mN − IrN − IHN − IHTBN )IH + υIHTB−
(γsλs + γrλr)IH − (dH + µ)IH
dIHTB
dt
= σsλHp2m+ σrλHIr + (γsλs + γrλr)IH − ωIHTB
(3.4.2)
where, is(0, t) = βscS
Ias
N
,
Ias (t) =
∮∞
0
p(α)is(α, t)dα, total number of active TB of drug-sensitive strain,
Is(t) =
∮∞
0
is(α, t)dα, total number of infected individuals with TB of drug-
sensitive TB (both latent and active TB are included)
Since the system of equations in (3.3.1) is non-linear, we take the linearized
one for our purpose as follows:
d = κsds + κrdr + κhdH ,
ω = µ+ υ + d,
p2 is the same as computed in chapter 2 and given as
p1 =
∮ t
0
e−(µ+ds)α−
∮ α
0 δ(s)dsdα ; which implies
p2 =
∮ t
0
p(α)e−(µ+ds)α−
∮ α
0 δ(s)dsdα.
Using the generating matrix approaches as [82] and from the above system
(3.4.2), we have:
z =

βscp2m
βrcIr + qrθp2m
βHcIH + νIHTB
(σsβHcp2 + σrβHc+ (γsλs + γrλr))IH
0

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ϑ =

m
(σrλH + µ+ η + dr)Ir
(µ+ dH)IH
(µ+ dH)IHTB
µN + dsp1m+ drIr + dHIH + (ω − µ− ν)IHTB

Hence, the matrices F and V for the new infection and the remaining transfer
terms are respectively given below:
F = ∂zi
xj
=

βscp2 0 0 0 0
qrθp2 βrc 0 0 0
0 0 βHc ν 0
0 0 0 σsβHcp2 + σrβHc 0
0 0 0 0 0

V = ∂ϑi
xj
=

1 0 0 0 0
0 µ+ η + dr 0 0 0
0 0 µ+ dH 0 0
0 0 0 ω 0
µ dsp1 dr dH d

From this we obtained the determinant of V and its inverse as follows:
det(V ) = ωd(µ+ dH)(µ+ η + dr),
V −1 =

1 0 0 0 0
0 1
µ+η+dr
0 0 0
0 0 1
µ+dH
0 0
0 0 0 1
ω
0
µ
ω−µ−ν
dsp1
d
dr
d
dH
d
1
d

.
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From the above, we have:
FV −1 =

βscp2 0 0 0 0
qrθp2
βrc
µ+η+dr
0 0 0
0 0 βHc
µ+dH
ν
ω
0
0 0 0 d
ω
0
0 0 0 0 0

=

Rs 0 0 0 0
qrθp2 Rr 0 0 0
0 0 RH
ν
ω
0
0 0 0 d
ω
0
0 0 0 0 0

.
Therefore, the eigenvalues of this is
det

(Rs − λ) 0 0 0 0
qrθp2 (Rr − λ) 0 0 0
0 0 (RH − λ) νω 0
0 0 0 ( d
ω
− λ) 0
0 0 0 0 −λ

= (Rs − λ)(Rr − λ)(RH − λ)( dω − λ)(−λ) = 0.
The dominant eigenvalues are the basic reproduction of TB,RTB = max(Rs, Rr)
as we did in chapter 2 for the system (2.2.1), basic reproduction of HIV, RH
that is obtained the HIV sub-model in the system (3.2.2). Thus, the basic re-
production of the system (3.3.1) denoted by R is given byR = max(RH , RTB)
which are the spectral radius of the operator FV −1.
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3.4.3 Positivity of solution
As we did in the previous chapter, the model system (3.3.1) above describes
the dynamics of a human population. Therefore; it is important to prove that
the state variables susceptible S(t), TB only infectious (i.e infectious with
drug sensitive strain Is(t) and infectious with drug resistant strain Ir(t), HIV
only infectious IH(t), and infectious with both HIV and TB, IHTB(t) infected
individuals are non-negative for all time t ≥ 0. For this model analysis, we
state and prove the next theorem.
Theorem 3.4.1. The feasible region in the set D = {(S, is, Ir, IH , IHTB)R5/N ≤
Λ
µ
} is positivity-invariant for system (3.3.1)
Proof. The rate of change of the total population computed from equation
of model (3.3.1) computed in the system of equations (3.3.2) is given by
dN
dt
= Λ− µN − drIr − dHIH − dIHTB − ds
∮ t
0
m(t− α)e−(µ+ds)α−
∮ α
0 δ(s)dsdα ≤
Λ− µN
which implies the feasible regionD = {(S(t), is(α, t), Ir(t), IH(t), IHTB)(t)R5/(S(t)+∮∞
0
is(α, t)dα + Ir(t) + IH + IHTB = N ≤ Λµ} and from equation(3.4.1) we
observed that lim supt→∞N ≤ Λµ . It is clear that dNdt ≤ Λµ , since N(0) ≤ Λµ .
And also from equation(3.3.1), we find that
dS
dt
= Λ− (λs + λr + λH)S − µS + (1− r+ ηqr)θIas ≥ (λs + λr + λH)S, which
implies that S(t) ≥ S(0)e−(λs+λr+λH+µ)t , for all t ≥ 0,
Similarly ;Is(t) ≥ Is(0)e−(µ+ds)t for all t ≥ 0,
Ir(t) ≥ Ir(0)e−(µ+dr+η+σrλH)t for all t ≥ 0,
IH(t) ≥ IH(0)e−(γsλs+γrλr+(dH+µ)t ,
IHTB(t) ≥ IHTB(0)e−ωt for all t ≥ 0.
Thus, all the above shows that the solution of the system(3.3.1) is greater or
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equal zero for all t ≥ 0.
Therefore, the limits of the system in (3.3.1) with initial conditions remained
in D and all the variables and parameters of it are non-negative for all t ≥ 0
in its interval of existence feasible region D.
Hence, D is positivity invariant and attracting. Thus the mathematical
model in(3.3.1) in the region D is epidemiologically well-posed.
In the next section, we study the equilibria and stability properties of our
model in (3.3.1).
3.4.4 Equilibria and stability properties of the model
In this section, we try to find the equilibria and determine the stability prop-
erties of the model in (3.3.1).
The disease free equilibria of the system in (3.3.1) is given by E0 = (Λ
µ
, 0, 0, 0, 0).
is asymptotically stable if R < 1 and unstable if R > 1,
where R = max(RTB, RH). Therefore, all the following diseases free and
epidemic equilibria satisfies the above.
Theorem 3.4.2. The disease free equilibrium of the model (3.3.1) is locally
asymptotically stable (both HIV and TB diseases will die out) if R < 1 oth-
erwise it is unstable if R > 1.
Proof. By substituting the diseases free equilibrium point to the system of
equations in (3.4.2) which is the reduced form of (3.3.1), and using theorem
2.4.3, we obtained the corresponding Jacobian matrix as shown below:
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J(E0) =

−µ −dsp1 −dr −dH −d
0 Rs − 1 0 0 0
0 qrθp2 βrc(1− 1Rr ) 0 0
0 0 0 βHc(1− 1RH ) ν
0 0 0 0 −ω

Here, the eigenvalues of this matrix are
λ1 = −µ,
λ2 = −ω,
λ3 = Rs − 1,
λ4 = βrc(1− 1Rr ),
λ5 = βHc(1− 1RH ).
Hence, the first,λ1 and the second, λ2 eigenvalues are always negative. The
third, λ3, fourth, λ4 and fifth, λ5 eigenvalues are negative if all Rs, Rr and RH
are less than unity, respectively. That means when both basic reproduction
numbers of TB and HIV are less than one (R = max(RTB, RTB) < 1). There-
fore, the disease free equilibrium of the model (3.3.1) is locally asymptotically
stable if R < 1 and it is locally asymptotically unstable if R > 1.
Similarly the endemic equilibria of the system (3.3.1) are shown in the
theorem 3.4.3 below.
Theorem 3.4.3. The endemic equilibrium of the model (3.3.1) is locally
asymptotically stable if R > 1 otherwise it is unstable if R < 1.
Proof. The endemic equilibria are obtained by equating the system (3.4.2)
which is the reduced form of (3.3.1) equals to zero.
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Λ− µN − dsp1m− drIr − dHIH − dIHTB = 0
βsc(1− p1mN − IrN − IHN − IHTBN )p2m−m = 0
βrc(1− p1mN − IrN − IHN − IHTBN )Ir − (σrλH + µ+ dr + η)Ir + qrθp2m = 0
βHc(1− p1mN − IrN − IHN − IHTBN )IH + υIHTB − (γsλs + γrλr)IH − (dH + µ)IH = 0
σsλHp2m+ σrλHIr + (γsλs + γrλr)IH − ωIHTB = 0.
From the second, and third equations of the system (3.4.2) respectively, we
obtained
(1− 1
Rs
)N = p1m+ Ir + IH + IHTB.
m = µ+η+dr
qrθp2
(1− Rr
Rs
+ σrλH
µ+η+dr
)Ir.
Again after solving the fourth, and fifth equations of the above system, we
found
IHTB =
µ+dH
ν
(1− RH
Rs
+ γsλs+γrλr
µ+dH
)IH ,
(σsλHp2m+ σrλHIr + (γsλs + γrλr)IH = ωIHTB.
By substituting m as we expressed in terms of Ir above, which gives us
(σrλH + γsλHp2x)Ir = (ωy − (γsλs + γrλr))IH ,
which is equivalent to
IH =
(σrλH+γsλHp2x)
(ωy−(γsλs+γrλr))Ir.
Where,
x = µ+η+dr
qrθp2
(1− Rr
Rs
+ σrλH),
y = µ+dH
ν
(1− RH
Rs
+ γsλs+γrλr
µ+dH
),
x
′
= σrλH+γsλHp2x
ωy−(γsλs+γrλr) ,
m = xIr,
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IH = x
′
Ir,
IHTB = x
′
yIr = yIH .
Here by substituting these values into the simplified form of the second equa-
tion of the system above, we found
(1− 1
Rs
)N = p1xIr + Ir + x
′
Ir + yx
′
Ir,
(p1x+ 1 + x
′
+ yx
′
)Ir = (1− 1Rs )N,
Ir =
(1− 1
Rs
)
(p1x+1+x
′+yx′ )N = x
′′
N,
Where, x
′′
=
(1− 1
Rs
)
(p1x+1+x
′+yx′ ) .
Finally we substituted all the values that we obtained in terms of N above
into the first equations of our system (3.4.2) and obtained the endemic equi-
librium denoted by E
′
= (N
′
,m
′
, I
′
r, I
′
H , I
′
HTB) is given as follows:
N
′
= Λ
µ+x′′ (dsp1x+dr+x′ (dH+dx))
,
I
′
r = x
′′
N,
m
′
= xx
′′
N,
I
′
H = x
′
x
′′
N,
I
′
HTB = yx
′
x
′′
N.
As we observed the system, according to the nature of equations, it is difficult
to solve the endemic equilibrium analytically as we did the disease free equi-
librium. Therefore we solve it numerically as shown in the following tables
using the parameters values used in tables (2.2.1) and (3.2.1).
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p(α) N
′
m
′
I
′
r I
′
H I
′
HTB
0.01 9884 1783.6 126.6 0 0
0.02 9912 1765.9 188.0 0 0
0.03 9939 1748.6 248.2 0 0
0.04 99656 1731.7 307.2 0 0
0.05 9991 1715.0 365.1 0 0
0.06 10017 1698.7 421.9 0 0
0.08 10042 1682.7 447.6 0 0
0.09 10066 1667.0 532.3 0 0
0.1 10090 1651.5 585.9 0 0
0.2 10308 1511.7 1072.6 0 0
0.3 10493 1393.7 1483.4 0 0
0.4 10650 1292.7 1834.6 0 0
0.5 10786 1205.5 2138.4 0 0
0.6 10905 1129.2 2403.7 0 0
0.7 11010 1062.0 2637.5 0 0
0.8 11103 1002.4 2845.0 0 0
1 11261 901.2 3197.2 0 0
Table 3.2: The solution of the endemic equilibrium when γs = γr = 1.5 with
initial solution (N
′
,m
′
, I
′
r, I
′
H , I
′
HTB) = (9856, 1801.6, 63.9, 0, 0) for RTB >
1, RH < 1.
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RH N
′
m
′
I
′
r I
′
H I
′
HTB
2.2 506.7 0 276.4 0
3 416.9 0 0 277.9 0
5 348.8 0 0 279.1 0
7 326 0 0 279.5 0
9 314.6 0 0 279.8 0
11 307.7 0 0 279.8 0
12 305.2 0 0 279.8 0
13 303.2 0 0 279.9 0
25 291.7 0 0 280.0 0
30 289.7 0 0 280.1 0
Table 3.3: The solution of the endemic equilibrium with initial solution
(N
′
,m
′
, I
′
r, I
′
H , I
′
HTB) = (1551.7, 0, 0, 258.6, 0) for RTB < 1, RH > 1.
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γs = γr N
′
m
′
I
′
r I
′
H I
′
HTB
2 11241 478.9 239.4 62.3 78.8
3 12351 486.6 243.3 42.2 80.1
4 13010 478.8 239.4 31.2 78.8
5 13473 463.5 231.7 24.1 76.3
7 14085 428.2 214.1 15.9 70.4
8 14297 411.7 205.9 13.4 67.8
9 14470 396.5 198.2 11.5 65.2
10 14626 380.3 190.1 9.9 62.5
13 14963 341.1 170.6 6.8 56.1
16 15207 307.2 153.6 5 50.5
18 15333 288.3 144.1 4.2 47.4
19 15386 280.0 140.0 3.8 46.1
20 15437 271.7 135.9 3.5 44.7
Table 3.4: The solution of the endemic equilibrium when γs = γr = 1.5
with initial solution (N
′
,m
′
, I
′
r, I
′
H , I
′
HTB) = (9465.3, 435.4, 217.7, 98, 93.1) for
RTB > 1, RH > 1.
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The above tables showed the endemic equilibrium of the system (3.3.1) and
(3.4.2) a result of the following three alternative cases.
• Table (3.2) showed the endemic equilibrium of TB with the basic re-
production of TB is greater than one while the basic reproduction of
HIV is less than one.
• Table (3.3) showed the endemic equilibrium of HIV with the basic re-
production of HIV is greater than one while the basic reproduction of
TB is less than one.
• Table (3.4) showed the endemic equilibrium of the system since both
basic reproductions of TB and HIV are greater than one.
Generally, all these cases implied the endemic equilibrium of HIV-TB
co-infection model (3.3.1) and (3.4.2), since basic reproduction num-
ber of the system is R = max(RTB, RH) > 1. Therefore, the endemic
equilibrium of the model in (3.3.1) judged and depended on the values
of the basic reproduction numbers of either TB disease in both drug-
sensitive and resistant strains or the basic reproduction of HIV or the
basic reproduction of both HIV and TB.
The following figures also showed the graph of the system (3.4.1) above at
the endemic equilibrium with different initial solutions or values of the com-
partments:
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Figure 3.3: The first two figures in the above showed, solution of sus-
ceptible to either TB or HIV on the left side and infected individual
with drug-sensitive TB on the right side. The second two figures showed
the solution of infected with drug-resistant TB on the left and HIV on
the right sides, respectively. The last one showed the solution of in-
fected with both HIV and TB (i.e infected with their co-infection). All
of the solutions are with initial value (S(0), is(0, 0), Ir(0), IH(0), IHTB(0)) =
(73171, 36277, 51640, 12623, 4734) and step sizes h = 0.01.
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Figure 3.4: The first two figures in the above showed, solution of suscep-
tible to either TB or HIV on the left side and infected individual with
drug-sensitive TB on the right side. The second two figures show the
solution of infected with drug-resistant TB on the left and HIV on the
right sides, respectively. And the last one shows the solution of infected
with both HIV and TB (i.e infected with their co-infection) with initial so-
lutions (S(0), is(0, 0), Ir(0), IH(0), IHTB(0)) = ((8201, 4065, 5788, 1415, 531))
and step sizes h = 0.5.
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Figure 3.5: The first two figures in the above showed, solution of suscep-
tible to either TB or HIV on the left side and infected individual with
drug-sensitive TB on the right side. The second two figures show the so-
lution of infected with drug-resistant TB on the left and HIV and the
right sides, respectively. The last one shows the solution of infected with
both HIV and TB (i.e infected with their co-infection) with initial so-
lutions (S(0), is(0, 0), Ir(0), IH(0), IHTB(0)) = (20000, 20, 3, 25, 5) and step
sizes h = 2.5 for R > 1.
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Generally, all the figures we observed in chapter 2 and chapter 3 showed the
convergence of the initial solution of the compartments with the tolerance
of susceptible, infected with drug-sensitive TB, infected with drug-resistant
81
Figure 3.6: The first two figures in the above showed, solution of suscep-
tible to either TB or HIV on the left side and infected individual with
drug-sensitive TB on the right side. The second two figures that are in
between the first two and the last one show the solution of infected with
drug-resistant TB and HIV on the left and the right sides, respectively.
And the last one shows the solution of infected with HIV and TB (i.e in-
fected with their co-infection). All of the solutions are with initial value
(S(0), is(0, 0), Ir(0), IH(0), IHTB(0)) = (6827, 3385, 4818, 1178, 442) and step
sizes h = 0.05.
TB, infected with HIV only, and infected with both HIV and TB ( their
co-infection) individuals are 40%,25%, 20%, 30% and 25%, respectively.
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Chapter 4
Formulation and analysis of
nonstandard finite difference
methods for HIV and TB
co-infection models
In this chapter, we construct the NSFDMs and this is done in two separate
sections. In the first section we construct the NSFDM for the sub-models
(HIV only sub-model and TB-only sub-models) while the numerical method
of the HIV-TB co-infections model is constructed in the second section of this
chapter. The positivity of the solutions considered in the previous chapters
are also shown in this method. In addition to these, comparison of other
literatures approach are also reviewed in this chapter.
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4.1 Introduction
In this chapter, the full model (3.3.1) of HIV and TB co-infection that ac-
counts for TB treatment will be formulated and analyzed, by considering sub
models (the TB and HIV only sub models) with their qualitative properties.
To come up with this, first we analyze and construct the NSFD numerical
methods for the sub models. The TB only sub model (2.2.1) accounts for
TB treatment that shows treatment impacts on TB with the age of infection
done in chapter 2 and (3.2.1) of HIV-only sub-models in chapter 3. Secondly
we check whether these numerical methods converge to the theoretical equi-
libria of the full model, by checking the convergence of numerical methods
for the sub models.
These methods were explored by many researchers to solve problems in the
biological science and other fields. A few of them are mentioned as follows:
In 2005 [48], Ronald E. Mickens introduced the concept of elementary sta-
bility, the property which brings correspondence between the local stability
at equilibria of the differential equation and the numerical method. In [33],
the NSFD methodology was used to constructed numerical method that is
dynamically consistent for a large class of dynamical systems used in epi-
demiology. The method was elementary stable and preserved some properties
including positivity solution, dissipative and globally asymptotic stability of
the disease free equilibrium. Villanueva et al. [56] developed NSFD schemes
to solve the numerical solution of a mathematical model of infant obesity
with constant population size. Their model consists of a system of cou-
pled nonlinear ordinary differential equations. The numerical results showed
that their methods have better convergence properties as compared to the
classical Euler or the fourth-order Runge-Kutta methods and the Matlab
routines in the sense that these routines give negative values for some of the
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state variables. Construction and Analysis of Efficient Numerical Methods
to Solve Mathematical Models of TB and HIV Co-infection was conducted
by Obaid Ahmed [32]. In their study competitive unconditionally stable
NSFDMs were proposed for solving a TB-only sub-model and a full HIV-TB
co-infection model represented by a nonlinear system of ordinary differential
equations. Numerical results presented, confirmed the applicability of the
proposed NSFDMs for the biological systems. These methods preserved the
positivity of solutions and converging to stability properties of the equilibria
for arbitrary step-sizes while the solutions obtained by other numerical meth-
ods experience difficulties in either preserving the positivity of the solutions
or in converging to the correct equilibria. As we observed from the literature
review in chapter 1 of this paper, several NSFDMs have been constructed for
specific ODEs and PDEs [32, 48, 49, 66, 68, 72, 92].
To summarize all the above, in this chapter, we develop and investigate the
applicability of the NSFDMs for numerical solution of systems of differential
equations in biology, and improve the order of convergence of these methods
both for ODE and PDE models expressed in (2.2.1), (3.2.1) and (3.3.1).
4.2 Formulation of nonstandard finite differ-
ence methods (NSFDMs)
To construct the NSFDMs for HIV-TB co-infections model and other sub-
models mentioned in the previous chapters, we begin with time domain [0,T]
which is partitioned as 0 = t0 < t1 < t2 < ... < tn−1 < tn = T (i.e. tn = nh,
where h > 0 is the time step-size).
In general, solving the systems of differential equations (2.2.1), (3.2.1) and
(3.3.1) by a finite difference method consists of the following four steps:
85
• Discretizing the domain:
The time domain [0, T] is represented by a mesh: a finite number of
n+1 points. 0 = t0 < t1 < t2 < ... < tn−1 < tn = T.
• Fulfilling the systems of equation at discrete time points:
The differential equations being valid for t” ∈ ”[0, T ] at mesh points
only.
• Replacing derivatives by finite differences:
Here, it is time for the finite difference approximation of derivatives.
• Formulating a recursive algorithm:
We seek the solution of our problem at the mesh points using the initial
value at one of the mesh point, then we get the computational formula
which is called recursive algorithm.
4.3 Formulation and analysis of NSFDMs for
HIV -only sub-model
In this section, we construct the NSFDMs for HIV-only sub-model (3.2.1).
The derivative is replaced by the finite difference as
dS
dt
= S(t+h)−S(t)
φ(h)
+O(φ(h)) as h→ 0.
Where φ(h) is a denominator function [32] which is a real valued function
and satisfies φ(h) = h+O(h2), for all h > 0.
We denote S(nh) by Sn, where
n = 0, 1, 2, ...., then the NSFDMs applied to the model (3.2.1) reads as:
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Sn+1−Sn
φ1(h)
= Λ− λHSn+1 − µSn+1
In+1H −InH
φ2(h)
= λHS
n+1 − (µ+ dH)In+1H
(4.3.1)
where,
φ1(h) =
eµh−1
µ
,
φ2(h) =
e(µ+dH )h−1
µ+dH
.
After simplifying the equations in (4.3.1), we obtained
Sn+1 = S
n+Λφ1(h)
1+φ1(h)(µ+cβH
In
H
Sn+In
H
)
In+1H =
InH(1+φ2(h)cβHS
n+1 Sn
Sn+In
H
)
1+φ2(dH+µ)
(4.3.2)
Remark 4.1: If the values of φ1(h)=h= φ2(h), then the numerical method is
called NSFDM-I [48, 72]. However, the numerical method is called NSFDM-
II when the values of φ1(h) and φ2(h) are different from h as shown in (4.3.1)
above.
We recall that the disease free equilibrium of the system (4.3.1) is given by
E0 = (Λ
µ
, 0) that was proved to be locally asymptotically stable if RH < 1
and unstable if RH > 1.
In the following subsections, we see the disease free and the endemic equilib-
ria of system (4.3.2) which is the simplified form of (4.3.1).
4.3.1 The numerical results and stability properties
of HIV at the disease free equilibria
In this subsection, we see the properties of the disease free equilibrium using
the following theorem.
87
Theorem 4.3.1. The disease free equilibrium of HIV in (4.3.1) is locally
asymptotically stable if the basic reproduction of HIV, RH < 1 while it is un-
stable if RH > 1 for real valued denominator functions φi(h) = h+O(h
2), i =
1, 2 and for all h > 0.
Proof. Here, we found the the partial derivatives of these functions of the
system (4.3.1) with respect to the given variables (Sn, InH) at the disease free
equilibrium E∗ = (S∗, I∗H) = (
Λ
µ
, 0) and the matrix entries as follows:
Let, J(X) =
 S
n+Λφ1(h)
1+φ1(h)(µ+cβH
In
H
Sn+In
H
)
InH(1+φ2(h)cβHS
n+1 Sn
Sn+In
H
)
1+φ2(dH+µ)
,
where, X = (Sn, InH).
Then,
∂J
∂X11
=
1+φ1(h)(µ+cβH
InH
Sn+In
H
)+(Sn+Λφ1(h))(
InH
(Sn+In
H
)2
)
(1+φ1(h)(µ+cβH
In
H
Sn+In
H
))2
= 1+φ1(h)µ
(1+φ1(h)µ)2
= 1
1+φ1(h)µ
,
∂J
∂X12
=
−(Sn+Λφ1(h))(φ1(h)cβH( I
n
H+S
n−InH
(Sn+In
H
)2
))
(1+φ1(h)(µ+cβH
In
H
Sn+In
H
))2
= −φ1(h)cβH(S
n)2−(φ1(h))2cβHΛSn
(Sn)2(1+φ1(h)µ)2
= −φ1(h)cβH(1+φ1(h)µ)
(1+φ1(h)µ)2
= −φ1(h)cβH
1+φ1(h)µ
,
∂J
∂X21
= φ2(h)cβH
1+φ2(µ+dH)
(
InH((1+φ1µ)(S
n+InH)+cβHI
n
H)−(1+φ1µ)InH(Sn+InH)
((1+φ1µ)(Sn+InH)+cβHI
n
H)
2
= 0( φ2(h)cβH
1+φ2(µ+dH)
)
= 0,
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∂J
∂X22
=
1+φ2(h)cβH(
(Sn+φ1(h)Λ)((1+φ1µ)(S
n+InH )+cβHI
n
H )−I
n
H (S
n+InH )(1+φ1µ+φ1cβH )
((1+φ1µ)(S
n+In
H
)+cβHI
n
H
)2
)
1+φ2(µ+dH)
=
1+φ2(h)cβH(
Sn+φ1Λ
(1+φ1µ)S
n )
1+φ2(µ+dH)
= 1+φ2(h)cβH
1+φ2(µ+dH)
.
(i. e, ∂J
∂Xij
=
 11+φ1(h)µ −φ1(h)cβH1+φ1(h)µ
0 1+φ2(h)cβH
1+φ2(µ+dH)
), i = 1, 2 and j = 1, 2 for Sn and
InH , respectively.
Therefore, the Jacobian matrix of the system (4.3.1) at the disease free equi-
librium is
J(E0) =
 11+φ1(h)µ −φ1(h)cβH1+φ1(h)µ
0 1+φ2(h)cβH
1+φ2(µ+dH)

Therefore, the eigenvalues of this matrix are obtained by solving
det

1
1+φ1(h)µ
− λ −φ1(h)cβH
1+φ1(h)µ
0 1+φ2(h)cβH
1+φ2(µ+dH)
− λ
 = 0
( 1
1+φ1(h)µ
− λ)( 1+φ2(h)cβH
1+φ2(µ+dH)
− λ) = 0
implies that
λ1 =
1
1+φ1(µ+cβH)
,
λ2 =
1+φ2cβH
1+φ2(µ+dH)
.
As observed from these eigenvalues the first one is less than while the second
is also less than one(unity) if and only if cβH < µ+dH , which is RH < 1.
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The following figures show the solutions of susceptible, S(t) for HIV on
the left sides and the infected individuals,IH(t) with HIV on the right sides
with initial values (S(0), IH(0)) = (178445, 0) at different step sizes h indi-
cated with the individual figure.
Remark 4.2 : Time(t) in all cases are measured in years.
Figure 4.1: This shows the solution of HIV with initial solution
(S(0), IH(0)) = (178440, 5) and step-size h = 0.125.
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Figure 4.2: This figure shows the solution of HIV with initial solution
(S(0), IH(0)) = (178000, 445) and step-size h = 0.5.
Figure 4.3: This shows the solution of HIV with initial solution
(S(0), IH(0)) = (178440, 5) and step size h = 1.5.
Figure 4.4: This shows the solution of HIV with initial solution
(S(0), IH(0)) = (120445, 50000) with step size h = 5.
As we observed in the above figures, when the values of h approaches to
zero, the solution of NSFDM of HIV in (4.2.1) approaches to the disease free
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equilibrium for different initial solution at different step sizes h as RH < 1 ).
Therefore, the system in (3.2.1) is locally asymptotically stable at the en-
demic equilibrium when RH < 1.
4.3.2 The numerical results and stability properties of
HIV at the endemic equilibria
In this subsection, we check the stability properties of our system above when
the equilibrium is endemic. Before we are going to prove the stability of the
endemic equilibrium of HIV model (4.3.1) equivalent to (4.3.2), we first see
the lemma’s of [87] as shown below.
Lemma 4.3.2. The quadratic equation f(λ) = λ2 − αλ + β = 0 has two
roots that satisfy |λi| < 1, i = 1, 2, if and only if the following conditions are
satisfied:
1. f(0) = β < 1,
2. f(−1) = 1 + α + β > 0,
3. f(1) = 1− α + β > 0.
Theorem 4.3.3. The epidemic equilibrium of HIV in (4.3.1) is locally asymp-
totically stable if RH > 1 while it is unstable if RH < 1 for real valued
denominator function φi(h) = h+O(h
2), i = 1, 2 and for all h > 0.
Proof. Here, we found the the partial derivatives of these functions of the
system (4.3.1) with respect to the given variables (Sn, InH) for
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J(Xij) =

Sn+Λφ1(h)
1+φ1(h)(µ+cβH
In
H
Sn+In
H
)
InH(1+φ2(h)cβH
Sn+Λφ1(h)
(1+φ1(h)µ)(S
n+In
H
)+φ1(h)cβHI
n
H
)
1+φ2(h)(dH+µ)
,
where, Xij = (S
n, InH),
are,
∂J
∂X11
=
1+φ1(h)(µ+dH)(1− 1RH )
1+φ1(h)µ+φ1(h)cβH(1− 1RH )
,
∂J
∂X12
= −φ1(h)(µ+dH)
(1+φ1(h)µ)RH+φ1(h)cβH(RH−1) ,
∂J
∂X21
= φ2(h)cβH(RH−1)
R2H(1+φ2(h)(µ+dH))
(
R2H+φ1(h)βHc(RH−1)
RH(1+φ1(h)µ)+φ1(h)βHc(RH−1) − 1),
∂J
∂X22
=
1+
φ2(h)(µ+dH )(1+φ1µ)
(1+φ1(h)µ)RH+φ1(h)cβH (RH−1)
1+φ2(h)(µ+dH)
.
THus at the epidemic equilibriumE1 = (S1, I1H) = (
Λ
µ+cβH(1− 1RH )
, Λ(RH−1)
µ+cβH(1− 1RH )
),
its jacobian matrix becomes:
J(E1) =

1+φ1(h)(µ+dH)(1− 1RH )
1+φ1(h)µ+φ1(h)cβH(1− 1RH )
−φ1(h)(µ+dH)
(1+φ1(h)µ)RH+φ1(h)cβH(RH−1)
φ2(h)cβH(RH−1)
R2H(1+φ2(h)(µ+dH))
(
R2H+φ1(h)βHc(RH−1)
RH(1+φ1(h)µ)+φ1(h)βHc(RH−1) − 1)
1+
φ2(h)(µ+dH )(1+φ1µ)
(1+φ1(h)µ)RH+φ1(h)cβH (RH−1)
1+φ2(h)(µ+dH)

Therefore, the eigenvalues of this matrix are obtained by solving the charac-
teristics as shown below.
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det
 x′ − λ x′′
x
′′′
x
′′′′ − λ
 = 0,
f(λ) = λ2 − αλ+ β = 0,
where,
x
′
=
1+φ1(h)(µ+dH)(1− 1RH )
1+φ1(h)µ+φ1(h)cβH(1− 1RH )
,
x
′′
= −φ1(h)(µ+dH)
(1+φ1(h)µ)RH+φ1(h)cβH(RH−1) ,
x
′′′
= φ2(h)cβH(RH−1)
R2H(1+φ2(h)(µ+dH))
(
R2H+φ1(h)βHc(RH−1)
RH(1+φ1(h)µ)+φ1(h)βHc(RH−1) − 1),
x
′′′′
=
1+
φ2(h)(µ+dH )(1+φ1µ)
(1+φ1(h)µ)RH+φ1(h)cβH (RH−1)
1+φ2(h)(µ+dH)
,
α = x
′
+ x
′′′′
,
β = x
′
x
′′′′
+ x
′′
x
′′′
.
From these Jacobian entries above, we observed the following for any step-
size h:
|x′ | < 1, since dH < cβH for RH > 1 and |x′′′′ | < 1, immediate for RH > 1.
where as −x′′ and x′′′ are both greater than zero for RH > 1.
As a result of these,
x
′
+ x
′′′′
= α > 0,
x
′
x
′′′′−x′′x′′′ = β > 0, since x′ ,−x′′ , x′′′ and x′′′′ are all greater than zero (0).
Therefore, according to lemma 4.2.2 above, we have:
f(0) = β = x
′
x
′′′′ − x′′x′′′ < 1,
f(−1) = 1 + α + β > 0,
f(1) = 1− α + β > 0. This completes the proof of the theorem.
94
In the following table, we can see the corresponding values of
the susceptible and infected individuals at the time step-sizes, h.
h S∗ I∗H λ1 λ2
0.5 117664 21010 0.992 1.064
3 107808 25919 0.957 1.352
5 83941 32154 0.921 1.551
8 52276 36494 0.876 1.804
10 25425 33731 0.848 1.946
15 7985 20905 0.781 2.230
Table 4.1: The following figures show the solutions of susceptible for HIV on
the left sides and the infected individuals with HIV on the right sides with
different initial solutions at different step sizes h indicated with the individual
figure.
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Figure 4.5: Solution of HIV with initial solutions with (S(0), IH(0)) =
(80445, 900000) and step size h = 0.05.
Figure 4.6: Solution of HIV with initial solutions with (S(0), IH(0)) =
(178440, 5) and step size h = 0.1.
Figure 4.7: This is the solution with of HIV with initial solution
(S(0), IH(0)) = (120445, 50000) and step size h = 0.1.
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Figure 4.8: This shows the solution of HIV with initial solution
(S(0), IH(0)) = (120445, 50000) and step size h = 0.5.
Figure 4.9: Solution of HIV with initial solution (S(0), IH(0)) =
(120445, 50000) and step size h = 1.5.
Remark 4.3: As the values of h approaches to zero, the solution of NSFDM
of HIV in (4.3.1) as we observed in the above figures approaches to the en-
demic equilibrium (i.e RH > 1).
Therefore, the system in (3.2.1) is locally asymptotically stable at the en-
demic equilibrium when RH > 1.
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4.4 Formulation and analysis of NSFDMs for
TB -only sub-model
In this section, we construct NSFDMs for the TB-sub-model in (2.2.1).
Following the same notations and approach as in the previous sections, the
NSFDMs of the model is written as follows:
Sn+1−Sn
φ1(h)
= Λ− (λs + λr + µ)Sn+1 + ηInr + (1− r)θi(n,j)s
(i
(n+1,j)
s −i(n,j)s )
φ2(h)
+ (i
(n,j+1)
s −i(n,j)s )
φ3(h)
= −z′i(n,j)s
(In+1r −Inr )
φ4(h)
= λrS
n+1 − (µ+ dr + η)In+1r + qrθi(n,j)s
(4.4.1)
The simplified form of (4.2.2.1) becomes
Sn+1 = S
n+φ1(h)(Λ+ηInr +(1−r)θi(n,j)s )
1+φ1(h)(µ+λr+λs)
i
(n+1,j)
s = (1 + z − φ2(h)z′)i(n,j)s − zi(n,j+1)s
In+1r =
Inr +φ4(h)(λrS
n+1+qrθi
(n,j)
s )
1+φ4(h)(µ+dr+η)
(4.4.2)
Where,
z = φ2(h)
φ3(h)
,
z
′
= (1− r + qr)θp(α) + µ+ ds,
φ1(h) =
eµh−1
µ
,
φ2(h) =
e(µ+ds)h−1
µ+ds
,
φ3(h) =
e(µ+dsρ(α))h−1
µ+dsρ(α)
,
φ4(h) =
e(µ+dr+η)h−1
µ+dr+η
.
In the following subsection we see the numerical results and the stability
properties of TB at diseases free and endemic equilibria.
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4.4.1 The numerical results and stability properties of
TB at the disease free equilibria
This section shows the numerical results and stability properties of (4.4.1)
above. We obtained the Jacobian matrix of TB sub-model at the disease free
equilibrium by taking the partial derivatives of the model (4.4.1) as follows:
Theorem 4.4.1. The disease free equilibrium of TB in (4.4.1) is locally
asymptotically stable if RTB < 1 while it is unstable if RTB > 1 for real
valued denominator functions φi(h) = h + O(h
2), i = 1, 2, 3, 4 and for all
h > 0.
Proof. To find the jacobian matrix of the system in (4.4.2) which is the sim-
plified form of (4.4.1) first we obtained the partial derivatives of the system
at the disease free equilibrium E∗ = (S∗(0), i∗s(0, 0), I
∗
r (0)) = (
Λ
µ
, 0, 0) as fol-
lows:
Let
G(X) =
(S
n+φ1(h)(Λ+ηInr +(1−r)θi(n,j)s )
1+φ1(h)(µ+λr+λs)
, (1+z−φ2(h)z′)i(n,j)s −zi(n,j+1)s , Inr +φ4(h)(λrSn+1+qrθi
(n,j)
s )
1+φ4(h)(µ+dr+η)
),
where,
X = (Sn, injs , I
n
r ).
∂G
∂X11
= 1
1+µφ1(h)
,
∂G
∂X12
=
φ1(h)((1−r)θ−Rsp2 )
1+µφ1(h)
,
∂G
∂X13
= φ1(h)(η−βrc)
1+µφ1(h)
,
∂G
∂X21
= 0,
∂G
∂X22
= 1 + z(1− p(α))− z′φ2(h),
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∂G
∂X23
= 0,
∂G
∂X31
= 0,
∂G
∂X32
= qrθφ4(h)
1+(µ+η+dr)φ4(h)
,
∂G
∂X32
= 1+βrcφ4(h)
1+(µ+η+dr)φ4(h)
.
And its jacobian matrix is
J(E∗) =

1
1+µφ1(h)
φ1(h)((1−r)θ−Rsp2 )
1+µφ1(h)
φ1(h)(η−βrc)
1+µφ1(h)
0 1 + z(1− p(α))− z′φ2(h) 0
0 qrθφ4(h)
1+(µ+η+dr)φ4(h)
1+βrcφ4(h)
1+(µ+η+dr)φ4(h)

The characteristic of this matrix becomes
det

1
1+µφ1(h)
− λ φ1(h)((1−r)θ−
Rs
p2
)
1+µφ1(h)
φ1(h)(η−βrc)
1+µφ1(h)
0 1 + z(1− p(α))− z′φ2(h)− λ 0
0 qrθφ4(h)
1+(µ+η+dr)φ4(h)
1+βrcφ4(h)
1+(µ+η+dr)φ4(h)
− λ

= ( 1
1+µφ1(h)
− λ)(1 + z(1− p(α))− z′φ2(h)− λ)( 1+βrcφ4(h)1+(µ+η+dr)φ4(h) − λ)
= 0.
Hence,
λ1 =
1
1+µφ1(h)
,
λ2 = 1 + z(1− p(α))− z′φ2(h),
λ3 =
1+βrcφ4(h)
1+(µ+η+dr)φ4(h)
,
and
|λi| < 1, for i = 1, 2, 3 when Rr < 1 and 1 < p(α) + z′φ3(h).
Therefore, the disease free equilibrium of the system (4.4.1) is locally asymp-
totically stable if RTB < 1 while it is unstable if RTB > 1.
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The following figures showed the solution of the system (4.4.1) at the
disease free equilibrium when RTB < 1.
Figure 4.10: The first on the left side shows the susceptible population for
TB and right on the infected individuals with drug-sensitive TB. The last
one shows the infected one with dug-resistant TB. The solution of NSFDM
of TB with initial solution (S(0), is(0, 0), Ir(0)) = (178400, 40, 5) and step
size h = 0.05.
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Figure 4.11: The first on the left side shows the susceptible population for
TB and right on the infected individuals with drug-sensitive TB. The last one
shows the infected one with dug-resistant TB. That is, this shows the solution
of the disease free equilibrium of TB with initial value (S(0), is(0, 0), Ir(0)) =
(178400, 40, 5) and step size h = 0.5 for n.
In general, the solution of NSFDM of TB sub-model in (4.4.1) (the solution of
the susceptible, infected with drug-sensitive TB, infected with drug-resistant
TB individuals), in the above figures converge to the solution at disease free
equilibrium for different initial solutions with different step-size h; particu-
larly when h approaches to zero and RTB < 1.
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Therefore, the system in (2.2.1) of chapter 2 and (4.4.1) in the above is locally
asymptotically stable at the disease free equilibrium when RTB < 1.
4.4.2 The numerical results and stability properties
of TB at the endemic equilibria
To find the Jacobian matrix of our system in (4.4.1) at the endemic equilib-
rium, we used the endemic equilibrium E∗ = (S∗,m∗, I∗r ) of TB model (2.2.1)
of chapter two which is given as
S∗ = ( Λ
µ+dsχ+
dr(1− 1Rs )
1+χ
)(1− (1− 1
Rs
)( χ+p1
(χ+1)p1
)),
m∗ =
Λχ(1− 1
Rs
)
µ+dsχ+
dr(1− 1Rs )
1+χ
,
I∗r =
Λ(1− 1
Rs
)
(µ+dsχ+
dr(1− 1Rs )
1+χ
)(1+χ)
,
where,
χ =
p1(µ+η+dr)(1−RrRs )
qrθp2
,
m∗ = λsS∗. Therefore, the partial derivatives of the system (4.4.2) at the
this endemic equilibrium are:
X = (Sn,mn, Inr ).
∂G
∂X11
= 1
1+φ1(h)(µ+λs+λr)
+ φ1(h)(λs + λr)(1 + µφ1(h) + χdsφ1(h) +
1− 1
Rs
1+χ
(dr +
η + (1−r)θχ
p1
− χ+p1
(1+χ)p1
)),
∂G
∂X12
= φ1(h)(1−r)θ
1+φ1(h)(µ+λs+λr)
+ φ1(h)
(1+φ1(h)(µ+λs+λr))2
(
(1− 1
Rs
)
1+χ
(χβsc + βrc − βsc)(1 +
µφ1(h) + φ1(h)dsχ+
(1− 1
Rs
)
1+χ
(η + dr +
(1−r)θχ
p1
− χ
p1
− 1)),
∂G
∂X13
= φ1(h)η
1+φ1(h)(µ+λs+λr)
+
λs+λr+
µ
N
−βrc
(1+φ1(h)(µ+λs+λr))2
(1+µφ1(h)+φ1(h)dsχ+φ1(h)
(1− 1
Rs
)
1+χ
(η+
dr +
(1−r)θχ
p1
− χ
p1
− 1)),
∂G
∂X21
= 0,
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∂G
∂X22
= 1 + z(1− p(α))− z′φ2(h),
∂G
∂X23
= 0,
∂G
∂X31
=
φ4(h)λr(
∂G
∂X11
− 1
N
)
1+φ4(h)(µ+η+dr)
,
∂G
∂X32
=
φ4(h)(qrθ+λr(
∂G
∂X12
−Sn+1
N
))
1+φ4(h)(µ+η+dr)
,
∂G
∂X33
=
1+φ4(h)λr(
∂G
∂X13
+
Sn+1(Sn+mns )
N
)
1+φ4(h)(µ+η+dr)
.
Therefore, the jacobian matrix of the NSFDMs (4.4.1) of TB model at the
endemic equilibrium becomes
J(E1) = ( ∂G
∂Xij
)3i,j=1
=

∂G
∂X11
∂G
∂X12
∂G
∂X13
0 1 + z(1− p(α))− z′φ2(h) 0
∂G
∂X31
∂G
∂X32
∂G
∂X33

The characteristic of this matrix is
det

∂G
∂X11
− λ ∂G
∂X12
∂G
∂X13
0 1 + z(1− p(α))− z′φ2(h)− λ 0
∂G
∂X31
∂G
∂X32
∂G
∂X33
− λ
 = 0
(1+z(1−p(α))−z′φ2(h)−λ)(λ2− ( ∂G∂X11 + ∂G∂X33 )λ+ ∂G∂X11 ∂G∂X33 − ∂G∂X13 ∂G∂X31 ) = 0
, which implies that
1 + z(1− p(α))− z′φ2(h)− λ = 0 or
λ2 − ( ∂G
∂X11
+ ∂G
∂X33
)λ+ ∂G
∂X11
∂G
∂X33
− ∂G
∂X13
∂G
∂X31
) = 0
Thus, we have the following:
• λ = 1 + z(1− p(α))− z′φ2(h),
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• λ2 − ( ∂G
∂X11
+ ∂G
∂X33
)λ+ ∂G
∂X11
∂G
∂X33
− ∂G
∂X13
∂G
∂X31
= 0
By rearranging the second equation above we obtained the simplified one as
∂G
∂X11
∂G
∂X33
− ∂G
∂X13
∂G
∂X31
=
∂G
∂X11
+
φ1(h)λr
Nn
∂G
∂X13
+φ4(h)λrSn+1
∂G
∂X11
( 1
Inr
− 1
Nn
)+ ∂G
∂X11
∂G
∂X13
λr(φ4(h)−φ1(h))
1+φ4(h)(µ+η+dr)
.
Using lemma 4.3.2, we have
f(λ) = λ2 − ( ∂G
∂X11
+ ∂G
∂X33
)λ+ ∂G
∂X11
∂G
∂X33
− ∂G
∂X13
∂G
∂X31
= 0,
f(0) =
∂G
∂X11
+
φ1(h)λr
Nn
∂G
∂X13
+φ4(h)λrSn+1
∂G
∂X11
( 1
Inr
− 1
Nn
)+ ∂G
∂X11
∂G
∂X13
λr(φ4(h)−φ1(h))
1+φ4(h)(µ+η+dr)
< 1 for
φ4(h) > φ1(h),
f(−1) = 1 + ∂G
∂X11
+ ∂G
∂X33
+ ∂G
∂X11
∂G
∂X33
− ∂G
∂X13
∂G
∂X31
> 0,
f(1) = 1− ( ∂G
∂X11
+ ∂G
∂X33
) + ∂G
∂X11
∂G
∂X33
− ∂G
∂X13
∂G
∂X31
> 0.
Thus, this completes the proof of the theorem and it is true when Rs > 1 as
shown in the first two partial derivatives. Therefore, the endemic equilibrium
is locally asymptotically stable when RTB > 1 otherwise it is unstable when
RTB < 1.
In the following, we see that figures show the solutions of susceptible, infected
with drug-sensitive and drug-resistant TB at some points of different initial
solutions for different step-sizes h.
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Figure 4.12: The first on the left side shows the susceptible individu-
als for TB and right on the infected individuals with drug-sensitive TB.
The last one shows the infected one with dug-resistant TB initial solution
(S(0), is(0, 0), Ir(0)) = (178000, 20, 5) and step size h = 0.05.
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Figure 4.13: The first on the left side shows the solutions of susceptible
individuals for TB and right one the infected individuals with drug-sensitive
TB. The last one shows the infected one with dug-resistant TB with initial
solution (S(0), is(0, 0), Ir(0)) = (178000, 20, 5) and step size h = 0.5.
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Figure 4.14: The first on the left side shows the susceptible individuals for
TB and right on the infected individuals with drug-sensitive TB. The last one
shows the infected one with dug-resistant TB. Generally, this shows the so-
lution of endemic equilibrium of TB with initial value (S(0), is(0, 0), Ir(0)) =
(80000, 90000, 8445) and step size h = 0.5.
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Figure 4.15: The first on the left side shows the susceptible individuals
for TB and right on the infected individuals with drug-sensitive TB. The
last one shows the infected one with dug-resistant TB with initial solution
(S(0), is(0, 0), Ir(0)) = (80000, 90000, 8445) and step size h = 2.
In general, the solution of NSFDM for the TB sub-model in (4.4.1)(the solu-
tion of the susceptible, infected with drug-sensitive TB, infected with drug-
resistant TB individuals), as shown in the above figures converge to the
solution at the endemic equilibrium for different initial solutions with differ-
ent step-size h, and for RTB > 1.
Therefore, the system (2.2.1) in chapter 2 which is equivalent to the system
(4.4.1) in chapter 4 is locally asymptotically stable at the endemic equilib-
rium when RTB > 1.
4.5 Formulation and analysis of NSFDMs for
HIV-TB co-infection full model
In this section, we construct NSFDMs for the co-infection model of HIV
and TB as observed the individual sub-models in the previous sections. The
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figures below show the NSFDMs of the co-infection of HIV and TB model
(3.3.1) indicated above.
The NSFDMs of the model is written as follows:
Sn+1−Sn
φ1(h)
= Λ− (λH + λr + λs)Sn+1 − µSn+1 + (1− r + ηqr)θi(n,j)s
(i
(n+1,j)
s −i(n,j)s )
φ2(h)
+ (i
(n,j+1)
s −i(n,j)s )
φ3(h)
= −(((1− r + qr)θ + δsλH)p(α) + µ+ ds)i(n,j)s
(In+1r −Inr )
φ4(h)
= λrS
n+1 − δrλHIn+1r − (µ+ dr)In+1 + (1− η)qrθi(n,j)s
(In+1H −InH)
φ5(h)
= λHS
n+1 + νInHTB − (γsλs + γrλr)In+1H − (µ+ dH)In+1H
(In+1HTB−InHTB)
φ6(h)
= δsλHi
(n,j)
s + δrλHI
n+1
r − (γsλs + γrλr)In+1H − ωIn+1HTB
(4.5.1)
where
λs =
βsi
(n,j)
s
Sn+i
(n,j)
s +Inr +I
n
H+I
n
HTB
,
λr =
βrInr
Sn+i
(n,j)
s +Inr +I
n
H+I
n
HTB
,
λH =
βHI
n
H
Sn+i
(n,j)
s +Inr +I
n
H+I
n
HTB
,
φ1(h) =
eµh−1
µ
,
φ2(h) =
e(µ+ds)h−1
µ+ds
,
φ3(h) =
e(µ+dsρ(α))h−1
µ+dsρ(α)
φ4(h) =
e(µ+dr)h−1
µ+dr
,
φ5(h) =
e(µ+dH )h−1
µ+dH
,
φ6(h) =
e(µ+ω)h−1
µ+ω
,
ω = ν + κsds + κrdr + κHdH .
The above equations are simplified and written as:
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Sn+1 = S
n+φ1(h)Λ+φ1(h)(1−r+ηqr)θi(n,j)s
1+φ1(h)(µ+λH+λr+λs)
i
(n+1,j)
s = (1 +
φ2(h)
φ3(h)
− φ2(h)(((1− r + qr)θ + δsλH)p(α) + µ+ ds)i(n,j)s
−φ2(h)
φ3(h)
i
(n,j+1)
s
In+1r =
Inr +φ4(h)(λrS
n+1+(1−η)qrθi(n,j)s )
1+φ4(h)(δrλH+µ+dr)
In+1H =
InH+φ5(h)(λHS
n+1+νInHTB)
1+φ5(h)(γsλs+γrλr+µ+dH)
In+1HTB =
InHTB+φ6(h)(λH(δsi
(n,j)
s +δrI
n
r )+(γsλs+γrλr)I
n+1
H )
1+φ6(h)(µ+ω)
(4.5.2)
For n = 0, 1, 2, ... and j = 0, 1, 2, ....
Here, we determine the numerical simulation and stability properties of the
system (4.5.2) and the simplified form of (4.5.1) both at the disease free and
endemic equilibrium in the following subsections.
4.5.1 The numerical results and stability properties
of the full model at the disease free equilibria
From the Jacobian matrix of the system in (4.5.2) above, we obtained the fol-
lowing Jacobian matrix of it at the disease free equilibrium E0(S0, i0s, I
0
r , I
0
H , I
0
HTB) =
(Λ
µ
, 0, 0, 0, 0).
Let G(X) =

Sn+φ1(h)Λ+φ1(h)(1−r+ηqr)θi(n,j)s
1+φ1(h)(µ+λH+λr+λs)
(1 + φ2(h)
φ3(h)
− φ2(h)(((1− r + qr)θ + δsλH)p(α) + µ+ ds)i(n,j)s − φ2(h)φ3(h)i
(n,j+1)
s
Inr +φ4(h)(λrS
n+1+(1−η)qrθi(n,j)s )
1+φ4(h)(δrλH+µ+dr)
InH+φ5(h)(λHS
n+1+νInHTB)
1+φ5(h)(γsλs+γrλr+µ+dH)
InHTB+φ6(h)(λH(δsi
(n,j)
s +δrI
n
r )+(γsλs+γrλr)I
n+1
H )
1+φ6(h)(µ+ω)

,
where X = (Sn, ins , I
n
r , I
n
H , I
n
HTB).
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From the system (4.5.2) which is the simplified form of (4.5.1) at the disease
free equilibrium, first by deriving the partial derivatives of the matrix with
respect to the component variables, we have:
J(E0) = ( ∂G
∂Xij
)5i,j=1 =
∂G
∂X11
∂G
∂X12
∂G
∂X13
∂G
∂X14
∂G
∂X15
∂G
∂X21
∂G
∂X22
∂G
∂X23
∂G
∂X24
∂G
∂X25
∂G
∂X31
∂G
∂X32
∂G
∂X33
∂G
∂X34
∂G
∂X35
∂G
∂X41
∂G
∂X42
∂G
∂X43
∂G
∂X44
∂G
∂X45
∂G
∂X51
∂G
∂X52
∂G
∂X53
∂G
∂X54
∂G
∂X55

=

1
1+µφ1(h)
φ1(h)((1−r)θ)−βsc
1+µφ1(h)
φ1(h)(Rr+
1−η
µ+η+dr
)
1+µφ1(h)
φ1(h)βHc
1+µφ1(h)
0
0 a 0 0 0
0 φ4(h)qrθ
1+φ4(h)(µ+η+dr)
1+φ4(h)(1+µφ1(h))βrc
φ4(h)(µ+η+dr)
0 0
0 0 0 1+φ5(h)βHc
1+φ5(h)(µ+dH)
φ5(h)
1+φ5(h)(µ+dH)
0 0 0 0 1
1+φ6(h)ω

a = 1 + z(1− p(α))− z′φ2(h)− λ,
b = 1+φ4(h)(1+µφ1(h))βrc
φ4(h)(µ+η+dr)
,
d =
φ1(h)(Rr+
1−η
µ+η+dr
)
1+µφ1(h)
. Then the characteristic equation of this model is
det

1
1+µφ1(h)
− λ φ1(h)(θ−rθ−βsc)
1+µφ1(h)
d φ1(h)βHc
1+µφ1(h)
0
0 a− λ 0 0 0
0 φ4(h)qrθ
1+φ4(h)(µ+η+dr)
b− λ 0 0
0 0 0 1+φ5(h)βHc
1+φ5(h)(µ+dH)
− λ φ5(h)
1+φ5(h)(µ+dH)
0 0 0 0 1
1+φ6(h)ω
− λ

= 0
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Hence, the eigenvalues of this matrix are:
λ1 =
1
1+µφ1(h)
,
λ2 = 1 + z(1− p(α))− z′φ2(h),
λ3 =
1+φ4(h)(1+µφ1(h))βrc
φ4(h)(µ+η+dr)
,
λ4 =
1+φ5(h)βHc
1+φ5(h)(µ+dH)
,
λ5 =
1
1+φ6(h)ω
.
We observed that all the eigenvalues are less than unity (|λi| < 1 for i =
1, 2, 3, 4, 5) and when both RTB < 1 and RH < 1. Therefore, the system in
(4.5.2 ) above is locally asymptotically stable at the disease free equilibrium
if R < 1 since R = max(RTB, RH) and otherwise it is unstable.
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4.5.2 The numerical results and stability properties of
the model at the endemic equilibria
In this subsection, we check the stability and convergence of the NSFDM
of the full-model (HIV-TB co-infection model) according to the value of the
tolerance of each of the compartment and the figures as observed at the end
of this section. At the nd of this section we generalize the convergency of the
NSFDM compared to the convergency of the system we discussed in chapter
3 section at the endemic equilibrium.
Let recall the simplified system of nonstandard finite methods equation (4.5.2)
and
G(X) =

Sn+φ1(h)Λ+φ1(h)(1−r+ηqr)θi(n,j)s
1+φ1(h)(µ+λH+λr+λs)
(1 + φ2(h)
φ3(h)
− φ2(h)(((1− r + qr)θ + δsλH)p(α) + µ+ ds)i(n,j)s − φ2(h)φ3(h)i
(n,j+1)
s
Inr +φ4(h)(λrS
n+1+(1−η)qrθi(n,j)s )
1+φ4(h)(δrλH+µ+dr)
InH+φ5(h)(λHS
n+1+νInHTB)
1+φ5(h)(γsλs+γrλr+µ+dH)
InHTB+φ6(h)(λH(δsi
(n,j)
s +δrI
n
r )+(γsλs+γrλr)I
n+1
H )
1+φ6(h)(µ+ω)

,
By substituting the solution of model we obtained in theorem 3.4.3 at the
endemic equilibrium, we obtained the following partial derivatives at the en-
demic in terms of N above of the system (3.4.2) and obtained the endemic
equilibrium denoted by E
′
= (N
′
,m
′
, I
′
r, I
′
H , I
′
HTB) is expressed in terms of
E
′
= (S
′
, i
′
s, I
′
r, I
′
H , I
′
HTB) is given as follows:
∂G
∂X11
=
1+φ1(µ+λs+λr+λH)+(S
n+φ1(Λ+ηInr +(1−r)mn))φ1(λs+λr+λH )Nn
(1+φ1(µ+λs+λr+λH))2
,
∂G
∂X12
=
φ1(1−r)(1+φ1(µ+λs+λr+λH))+(Sn+φ1(Λ+ηInr +(1−r)mn))φ1(λs+λr+λH−βsc)Nn
(1+φ1(µ+λs+λr+λH))2
,
∂G
∂X13
=
ηφ1(1+φ1(µ+λs+λr+λH))+(S
n+φ1(Λ+ηInr +(1−r)mn))φ1(λs+λr+λH−βrc)Nn
(1+φ1(µ+λs+λr+λH))2
,
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∂G
∂X14
=
(Sn+φ1(Λ+ηInr +(1−r)mn))φ1(λs+λr+λH−βHc)Nn
(1+φ1(µ+λs+λr+λH))2
,
∂G
∂X15
= (S
n+φ1(Λ+ηInr +(1−r)mn))φ1(λs+λr+λH)
Nn(1+φ1(µ+λs+λr+λH))2
,
∂G
∂X21
= φ2σspαλH i
n,j
s
Nn
,
∂G
∂X22
= 1 + φ2
φ3
− φ2(((1− r + qr)θ + σsλH)p(α) + µ+ ds) + φ2σspαλH i
n,j
s
Nn
,
∂G
∂X23
= φ2σspαλH i
n,j
s
Nn
,
∂G
∂X24
= φ2σspα(λH−βHc)i
n,j
s
Nn
,
∂G
∂X25
= φ2σspαλH i
n,j
s
Nn
,
∂G
∂X31
=
φ4λr(
∂G
∂X11
−Sn+1
Nn
)
1+φ4(µ+η+dr+σrλH
+ φ4σrλH(I
n
r +φ4λrS
n+1+φ4qrθi
n,j
s )
Nn(µ+η+dr+σrλH)2
,
∂G
∂X32
=
φ4λr(
∂G
∂X12
−Sn+1
Nn
)+qrθ
1+φ4(µ+η+dr+σrλH
+ φ4σrλH(I
n
r +φ4λrS
n+1+φ4qrθi
n,j
s )
Nn(µ+η+dr+σrλH)2
,
∂G
∂X33
=
1+φ4βrc
(N−Inr )Sn+1
(Nn)2
+φ4λr
∂G
∂X13
(µ+η+dr+σrλH)2
+ φ4σrλH(I
n
r +φ4λrS
n+1+φ4qrθi
n,j
s )
Nn(µ+η+dr+σrλH)2
,
∂G
∂X34
=
φ4λr(
∂G
∂X14
−Sn+1
Nn
)
1+φ4(µ+η+dr+σrλH
+ φ4σrλH(I
n
r +φ4λrS
n+1+φ4qrθi
n,j
s )
Nn(µ+η+dr+σrλH)2
,
∂G
∂X35
=
φ4λr(
∂G
∂X15
−Sn+1
Nn
)
1+φ4(µ+η+dr+σrλH)
+ φ4σrλH(I
n
r +φ4λrS
n+1+φ4qrθi
n,j
s )
Nn(µ+η+dr+σrλH)2
,
∂G
∂X41
=
φ5λH(
∂G
∂X11
−Sn+1
Nn
)
1+φ5(µ+dH+λsλs+λrλr)
+
φ5(λsλs+λrλr)(InH+φ5I
n
HTB+φ5λHS
n+1)
Nn(1+φ5(µ+dH+λsλs+λrλr))2
,
∂G
∂X42
=
φ5λH(
∂G
∂X12
−Sn+1
Nn
)
1+φ5(µ+dH+λsλs+λrλr)
+
φ5(λsλs+λrλr)(InH+φ5(I
n
HTB+λHS
n+1))
Nn(1+φ5(µ+dH+λsλs+λrλr))2
,
∂G
∂X43
=
φ5λH(
∂G
∂X13
−Sn+1
Nn
)
1+φ5(µ+dH+λsλs+λrλr)
+
φ5(
γsλs
Nn
+
γrβsc(N
n−in,js )
(Nn)2
)(InH+φ5(I
n
HTB+λHS
n+1))
Nn(1+φ5(µ+dH+γsλs+γrλr))2
,
∂G
∂X44
=
1+φ5λH(
∂G
∂X14
+S
n+1
Nn
)
1+φ5(µ+dH+λsλs+λrλr)
+
φ5(γsλs+γrλr)(InH+φ5(I
n
HTB+λHS
n+1))
Nn(1+φ5(µ+dH+γsλs+γrλr))2
,
∂G
∂X45
=
φ5(1+λH(
∂G
∂X15
+S
n+1
Nn
))
1+φ5(µ+dH+λsλs+λrλr)
+
φ5(γsλs+γrλr)(InH+φ5(I
n
HTB+λHS
n+1))
Nn(1+φ5(µ+dH+γsλs+γrλr))2
,
∂G
∂X51
=
φ6((γsλs+γrλr)InH−(σsi
(n,j)
s +σrI
n
r )λH)
Nn(1+φ6ω)
,
∂G
∂X52
=
φ6(
σsλHi
(n+1,j)
s
Nn
+σsλH
∂G
∂X22
+
σrλHI
n+1
r
Nn
+
(γsλs+γrλr−βsc)In+1H
Nn
)
(1+φ6ω)
,
∂G
∂X53
=
φ6(
−(σsλHi
(n+1,j)
s )+σrλHI
n+1
r
Nn
+σrλH
∂G
∂X33
+
(γsλs+γrλr−βrc)In+1H
Nn
)
(1+φ6ω)
,
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∂G
∂X54
=
φ6((γsλs+γrλr)(
In+1
H
Nn
− ∂G
∂X44
)+(σsi
(n+1,j)
s +σrI
n+1
r )(λH−βHc))
Nn(1+φ6ω)
,
∂G
∂X55
=
1+φ6((γsλs+γrλr)I
n+1
H −(σsi
(n+1,j)
s +σrI
n+1
r )λH)
Nn(1+φ6ω)
,
For,
x = µ+η+dr
qrθp2
(1− Rr
Rs
+ σrλH),
y = µ+dH
ν
(1− RH
Rs
+ γsλs+γrλr
µ+dH
),
x
′
= σrλH+γsλHp2x
ωy−(γsλs+γrλr) ,
x
′′
=
(1− 1
Rs
)
(p1x+1+x
′+yx′ ) .
N
′
= Λ
µ+x′′ (dsp1x+dr+x′ (dH+dx))
,
Sn = N
′ − x′′N − xx′′N − x′x′′N − yx′x′′N
= (1− x′′ − xx′′ − x′x′′ − yx′x′′) Λ
µ+x
′′
(dsp1x+dr+x
′ (dH+dx))
,
m
′
= xx
′′
N,
I
′
r = x
′′
N,
m
′
= xx
′′
N,
I
′
H = x
′
x
′′
N,
I
′
HTB = yx
′
x
′′
N.
Using the above information, we obtained the following Jacobian matrix at
the endemic equilibrium E1(S1,m1, I1r , I
1
H , I
1
HTB) =
((1− x′′ − xx′′ − x′x′′ − yx′x′′)N, xx′′N, x′′N, x′x′′N, yx′x′′N)
J(E1) = ( ∂G
∂Xij
)5i,j=1 =
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
∂G
∂X11
∂G
∂X12
∂G
∂X13
∂G
∂X14
∂G
∂X15
∂G
∂X21
∂G
∂X22
∂G
∂X23
∂G
∂X24
∂G
∂X25
∂G
∂X31
∂G
∂X32
∂G
∂X33
∂G
∂X34
∂G
∂X35
∂G
∂X41
∂G
∂X42
∂G
∂X43
∂G
∂X44
∂G
∂X45
∂G
∂X51
∂G
∂X52
∂G
∂X53
∂G
∂X54
∂G
∂X55

Then its characteristics becomes
det

∂G
∂X11
− λ ∂G
∂X12
∂G
∂X13
∂G
∂X14
∂G
∂X15
∂G
∂X21
∂G
∂X22
− λ ∂G
∂X23
∂G
∂X24
∂G
∂X25
∂G
∂X31
∂G
∂X32
∂G
∂X33
− λ ∂G
∂X34
∂G
∂X35
∂G
∂X41
∂G
∂X42
∂G
∂X43
∂G
∂X44
− λ ∂G
∂X45
∂G
∂X51
∂G
∂X52
∂G
∂X53
∂G
∂X54
∂G
∂X55
− λ

= 0
Here, since to find the eigenvalues of the Jacobian matrix in terms of the
given variables is to large and somewhat difficult so that it better to find
its eigenvalues by taking specific (fixed) values for the variables. Hence we
obtained the following eigenvalues of the above characteristics at the endemic
equilibrium for (i.e R = max(RH , RTB) > 1 or RH > 1 and RTB > 1).
h S(0) is(0, 0) Ir(0) IH(0) IHTB(0) λ1 λ2 λ3 λ4 λ5
0.05 8201 4066 5788 1415 531 -4.4050 -0.0020 -0.1801 -0.9637 -2.2002
8 73171 36277 51640 12623 4734 -7.9196 -0.0204 -0.9153 -1.7013 -3.2034
15 2945 1941 686 158 41 -1.2934 -1.2934 -0.0020 -0.7820 -2.0002
Table 4.2: This table showed the negative eigenvalues of the above character-
istics equation as we did in theorem 2.4.1 and corollary 2.4.2 with different
initial solutions at the endemic equilibrium for RTB > 1, RH > 1.
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The following figures (4.16, 4.17, 4.18, 4.19, 4.20 and 4.21) showed the
solutions of susceptible to either TB or HIV, infected individuals with drug-
sensitive and drug-resistant to TB, infected with HIV, and infected with
both HIV and TB at the endemic equilibria with different initial solutions
and step-sizes h.
118
Figure 4.16: The first two figures in the above show, solutions of suscep-
tible to either TB or HIV on the left side and infected individual with
drug-sensitive TB on the right side. The second two figures that are in
between the first two and the last one show the solutions of infected with
drug-resistant TB and HIV on the left and the right sides, respectively. The
last one shows the solution of infected with HIV and TB or infected with
their co-infection with initial solutions (S(0), is(0, 0), Ir(0), IH(0), IHTB(0)) =
((8201, 4065, 5788, 1415, 531)) and step sizes h = 1.5.
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Figure 4.17: The first two figures in the above show, solutions of susceptible
to either TB or HIV on the left side and infected individual with drug-
sensitive TB on the right side. The second two figures that are in between the
first two and the last one show the solutions of infected with drug-resistant
TB and HIV on the left and the right sides, respectively. The last one
shows the solution of infected with their co-infection) with initial solutions
(S(0), is(0, 0), Ir(0), IH(0), IHTB(0)) = (7317, 3627, 30000, 8000, 4734) and at
the step sizes h = 0.8.
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Figure 4.18: The first two figures in the above showed, solution of suscep-
tible to either TB or HIV on the left side and infected individual with
drug-sensitive TB on the right side. The second two figures that are in
between the first two and the last one show the solution of infected with
drug-resistant TB and HIV on the left and the right sides, respectively.
The last one shows the solution of infected with HIV and TB and with ini-
tial value (S(0), is(0, 0), Ir(0), IH(0), IHTB(0)) = (20000, 20, 3, 25, 5) and step
sizes h = 0.1.
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Figure 4.19: The first two figures in the above showed, solution of susceptible
to either TB or HIV on the left side and infected individual with drug-
sensitive TB on the right side. The second two figures that are in between
the first two and the last one show the solution of infected with drug-resistant
TB and HIV on the left and the right sides, respectively. But the last one
shows the solution of infected with both HIV and TB. These are the solutions
of the individuals with initial solution (S(0), is(0, 0), Ir(0), IH(0), IHTB(0)) =
(1500, 30000, 1000, 20000, 4734) and step sizes h = 8.
123
Figure 4.20: The first two figures in the above showed, solution of suscep-
tible to either TB or HIV on the left side and infected individual with
drug-sensitive TB on the right side. The second two figures that are in
between the first two and the last one show the solution of infected with
drug-resistant TB and HIV on the left and the right sides, respectively.
The last one shows the solution of infected with HIV and TB. All of
the solutions are with initial value (S(0), is(0, 0), Ir(0), IH(0), IHTB(0)) =
(73171, 36277, 51640, 12623, 4734) and step sizes h = 0.1.
124
125
Figure 4.21: The first two figures in the above showed, solution of susceptible
to either TB or HIV on the left side and infected individual with drug-
sensitive TB on the right side. The second two figures that are in between the
first two and the last one show the solution of infected with drug-resistant TB
and HIV on the left and the right sides, respectively. The last one shows the
solution of infected with HIV and TB (i.e infected with their co-infection). All
of the solutions are with initial value (S(0), is(0, 0), Ir(0), IH(0), IHTB(0)) =
(6827, 3385, 4818, 1178, 442) and step sizes h = 0.05.
Generally, we summarized the solutions of NSFDM for HIV only sub-
model is locally asymptotically stable at the disease free equilibrium and
unstable at the endemic equilibrium when RH < 1. Otherwise it is vicev-
ersa. It is equivalent to the stability and unstably of HIV model in (3.2.1).
Similarly, the NSFDM formulated for TB only sub-model in this chapter has
equivalent locally asymptotically stability property at the endemic equilibria
and unstable at the disease free equilibrium when RTB > 1, respectively as
we computed for TB model in (2.2.1).
Lastly, the NSFDM of the full model of HIV-TB co-infection in (4.5.1) and
(4.5.2) has the same stability and unstability property as we did in the HIV-
TB co-infection model (3.3.1) in chapter 3. The solutions of the susceptible,
infected with drug-sensitive and drug-resistant TB, infected with HIV, and
infected with both HIV and TB individuals) in the above figures converge
to the equilibria for different initial solutions at different step-size h. As
we observed from the figures all above, particularly when h approaches to
zero,the initial solutions more converges to their equilibria with the tolerance
of susceptible, infected with drug-sensitive TB, infected with drug-resistant
TB, infected with HIV and infected with both HIV and TB ( their con-
126
fection) individuals are 2%, 1%,1%,7% and 2% respectively. Compared to
the convergency of our model in chapter 2 and 3, the (NSFDM ) numerical
method developed in this thesis converges the solutions with less tolerance
either to the disease free or the endemic equilibria as shown in all the fig-
ures throughout the chapters. In case of the positivity of its solution all the
solutions were showing positive values. Therefore, the system in (3.3.1) and
our NSFDM of the system (4.5.1) are locally asymptotically stable at the
endemic equilibrium when R > 1. Otherwise it is unstable.
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Chapter 5
Conclusion, recommendations
and future work
In this thesis, we constructed and analyzed the nonstandard finite difference
numerical method for HIV-TB co-infection with treatment model. Here first
we studied the sub-models (HIV-only and TB-only) and then the full model
HIV-TB co-infection.
In chapter 2, we developed and analyzed a mathematical model describing
the dynamics of TB with age of infection. The model accounts for one-strain
model at the age of infection with drug sensitive TB. By assuming the pro-
portion of the sensitive strain, p(α) (which active at the infection age (α)
that has of form 0 ≤ p(α) ≤ 1 which is neither negative nor increasing func-
tion. The drug resistant strain accounts active TB only. Drug-resistant and
drug-sensitive strains are modeled, but only the age of the infection with
drug-sensitive strain is considered. Since is(α, t) is a function of two inde-
pendent continuous variables we have a PDE in the model which makes the
model more complicated than the models based on ODE.
Chapter 3 investigated the above approach to study HIV sub-model and a co-
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infection of HIV-TB model. In this chapter, the model developed in chapter
2 is combined with HIV model to formulate tuberculosis and a deterministic
model of HIV and TB co-infection. In this section, we study the stability
of the disease-free equilibrium, and the endemic equilibrium. To this end,
the effects of TB treatment on the dynamics of HIV-TB co-infections were
investigated.
In Chapter 4, at the first stage we constructed and analyzed robust numerical
methods (NSFDMs) that solve TB sub-model with both strains in chapter
2 and HIV sub-model in chapter 3. At the second stage, we constructed the
NSFDM that solve the HIV-TB co-infection model presented in chapter 3.
The models we formulated the first two chapters were investigated using the
NSFDM of numerical method developed in the chapter 4 in detail.
The solution of the HIV only sub-model, TB only sub-model and the full
model of HIV-TB co-infection were transferred to the NSFDM in the fourth
chapter, (the solutions of the susceptible, infected with drug-sensitive and
drug-resistant TB, infected with HIV, and infected with both HIV and TB
individuals) in the above figures converge to the equilibria for different ini-
tial solutions at different step-size h. In addition to this, the positivity of its
solutions were also shown through the whole chapters which is coincide with
epidemiological concepts of the positivity of human beings. The NSFDM
more converges the initial solutions to their equilibria with tolerance of sus-
ceptible, infected with drug-sensitive TB, infected with drug-resistant TB,
infected with HIV and infected with HIV-TB co-infection individuals are 2%,
1%,1%,7% and 2% respectively. Compared to the convergency of our model
in chapters 2 and 3, the numerical method (NSFDM )developed in this thesis
converges the solutions with less tolerance either to the disease free or the
endemic equilibria as shown in all the figures considered.
129
Moreover, we computed the basic reproduction numbers for TB, RTB and
HIV,RH and the overall reproduction number for the systemR = max(RH , RTB).
After the computation was over according to the values of the overall basic
reproduction number if R < 1 then the disease-free equilibrium is locally
asymptotically stable and the endemic equilibria is asymptotically unstable
respectively. Otherwise it is viceversa. The TB-only endemic equilibrium is
locally asymptotically stable if RTB > 1, and RH < 1. However, the sym-
metric condition, RTB < 1 and RH > 1, does not necessarily guarantee the
stability of the HIV-only equilibrium, but it is possible that TB can coexist
with HIV when RH > 1, due to the inactive (latent) existence of TB in the
human beings, particularly the HIV-TB co-infection with TB treatment in
Ethiopia.
Furthermore, the asymptotically stable and unstable properties of the mod-
els of TB only sub-model (2.2.1), HIV only sub-model (3.2.1) and the full
model of HIV-TB co-infection (3.3.1) were equivalent to the NSFDM of TB
only sub-model (4.4.1), the HIV only sub-model (4.3.1) and the NSFDM of
the full model of HIV-TB co-infection (4.5.1), respectively.
The method developed in this thesis works for first order mixed ODE and
PDE as we observed in our model. Hence some of the scope our future re-
search become the order of convergence of the method, the applicability of
the method for second and above order ODE and PDE of epidemiological
models.
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